{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Mitochondrial Dysfunction Hypothesis", "entry_form": "phenomenon", "gradeable_restatement": "Age-related mitochondrial bioenergetic failure is a primary upstream causal driver of neurodegeneration, initiating rather than following proteinopathies in sporadic Alzheimer’s, Parkinson’s, Huntington’s disease and ALS.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Baseline disease and genotype, neuronal lineage, age, respiratory lesion, mutant-protein expression, treatment stage and exposure", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ] }, "hypothesis": { "name": "Mitochondrial Dysfunction Hypothesis", "central_claim": "Age-related mitochondrial bioenergetic failure is a primary upstream causal driver of neurodegeneration, initiating rather than following proteinopathies in sporadic Alzheimer’s, Parkinson’s, Huntington’s disease and ALS.", "proposed_mechanism": "Age-related mitochondrial bioenergetic failure is a primary upstream causal driver of neurodegeneration, initiating rather than following proteinopathies in sporadic Alzheimer’s, Parkinson’s, Huntington’s disease and ALS.", "claimed_scope": "Age-related sporadic AD, PD and ALS primacy; inherited HTT HD retained as a separate genetically initiated contrast", "claimed_level": [ "initiation", "progression" ], "is_conjunctive": true, "conjunctive_note": "Use the index mitochondrial-first claim. Score forced lesions, HD biogenesis and PD mtDNA separately; SC5 gates the broad etiological-apex inference. Human treatment results are a separate application rather than an obligatory antioxidant clause." }, "rubric_routing": { "primary_rubric": "01-neurodegeneration.md", "secondary_rubrics": [ "06-metabolism-aging.md" ], "index_notes_applied": [ "Use the index mitochondrial-first claim. Score forced lesions, HD biogenesis and PD mtDNA separately; SC5 gates the broad etiological-apex inference. Human treatment results are a separate application rather than an obligatory antioxidant clause." ], "rubric_fit_note": "Exact archived v5.3 framework. Any stale index empirical framing is rechecked against primary results." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Mitochondrial deficits are present in neurodegenerative tissue.", "subclaim_type": "existence", "scope": "AD, PD, HD and ALS tissue", "claimed_scope": "AD, PD, HD and ALS tissue", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Cell-resolved respiratory and genetic measurements", "hsef_level": "Β", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Respiratory, mtDNA and metabolic abnormalities are reproducibly present, but variation by cell, disease and preparation is substantial. A descriptive tissue association is Β; it neither negates nor supplies causal perturbation." }, { "id": "SC2", "statement": "Loss of mitochondrial function causes progressive neurodegeneration in vivo.", "subclaim_type": "sufficiency", "scope": "prespecified neuronal genetic lesions and toxins", "claimed_scope": "prespecified neuronal genetic lesions and toxins", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Controlled loss with cell survival and rescue", "hsef_level": "Ζ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Tfam disruption, conditional adult Parkin/PARIS loss with Nissl-confirmed degeneration, combined POLG/Parkin stress and rat complex-IV editing provide distinct endogenous routes to disease-relevant injury. Model-level mitochondrial sufficiency reaches Ζ as a set. Ndufs2 primarily produces dysfunction with somatic survival and is not falsely counted as death. Contradictory pore effects and lesion severity block a uniform Η trajectory claim; sporadic human primacy is a separate subclaim." }, { "id": "SC3", "statement": "Mitochondrial biogenesis supports striatal survival in HD models.", "subclaim_type": "necessity", "scope": "defined HD and PGC-1α settings", "claimed_scope": "defined HD and PGC-1α settings", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Endogenous biogenesis perturbation and rescue", "hsef_level": "Ε", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Endogenous PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice and matched gain-of-function/PPAR approaches preserve phenotypes. This is genuine context-dependent biogenesis contribution (Ε), despite pleiotropy. Mutant HTT is upstream; donor-cell glycolytic and isolated-respiration counterexamples limit generalization and exclusive bioenergetic explanation." }, { "id": "SC4", "statement": "Somatic mtDNA deletion burden drives selective neuronal loss in sporadic PD.", "subclaim_type": "primacy", "scope": "age-related substantia nigra mtDNA burden", "claimed_scope": "age-related substantia nigra mtDNA burden", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Deletion-selective manipulation and longitudinal cell fate", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Single-cell deletion burden has a plausible respiratory effect and healthy aged cells compensate, but no deletion-selective pre-onset manipulation tracks sporadic PD neuron fate. POLG/Parkin point-mutation interaction is not the same lesion. Combined mechanistic support gives Γ, not demonstrated deletion primacy." }, { "id": "SC5", "statement": "Bioenergetic failure is the upstream etiological apex across sporadic neurodegeneration.", "subclaim_type": "primacy", "scope": "disease classes specified before outcomes", "claimed_scope": "disease classes specified before outcomes", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Temporal bidirectional causal separation from proteinopathy", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Mitochondrial-first engineered models and transferred cybrids coexist with protein-first import, permeability and immune pathways. No human temporal/counterfactual set establishes an etiological apex across sporadic AD, PD and ALS. Genetic HD starts with HTT, and mitochondria can modify its consequences. Γ applies to the broad initiating inference, not to the assembled narrow lesion causality." }, { "id": "SC6", "statement": "Restoring mitochondrial function changes human disease trajectory.", "subclaim_type": "mechanism", "scope": "human disease-specific clinical interventions", "claimed_scope": "human disease-specific clinical interventions", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Mechanistic engagement and function or survival", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Large PD/ALS/HD drug trials are often null, but adequate neuronal engagement is not universally demonstrated. UDCA and NADPARK demonstrate human bioenergetic/metabolic changes without confirmed disease modification. Restricted edaravone functional benefit is not a selective mitochondrial restoration experiment. Mechanistically attributable clinical trajectory change remains Γ." } ], "aggregation_rule": "scope-matched", "aggregation_preregistered": true, "aggregation_rationale": "Use the index mitochondrial-first claim. Score forced lesions, HD biogenesis and PD mtDNA separately; SC5 gates the broad etiological-apex inference. Human treatment results are a separate application rather than an obligatory antioxidant clause.", "primary_subclaim_id": "SC5", "aggregation_derivation": "Scope-matched SC5 gives Γ. Endogenous mitochondrial lesions demonstrate convergent model causality (SC2 Ζ), and HD biogenesis has contextual contribution (SC3 Ε). Neither set identifies age-related respiratory failure as the spontaneous upstream cause across disease classes. The registered phrase sporadic Huntington disease is scientifically ill-posed: the examined HTT disease is genetically initiated, and is retained as an explicit counterexample rather than silently recast.", "aggregation_alternatives": { "weakest_link_would_return": "Β", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "Separate narrow successes do not replace the preregistered gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M4", "is_nominal": false, "name": "Multi-hit convergent loop", "core_claim": "Genotype, proteinopathy, organelle quality control and inflammation converge on conditional metabolic vulnerability.", "explains_what_nominal_does_not": "Genotype, proteinopathy, organelle quality control and inflammation converge on conditional metabolic vulnerability.", "strongest_supporting_evidence": [ "Parkin/POLG interaction, protein-led import disruption, NCLX/USP30 rescue and variable PD complex-I subtypes support bounded reciprocal contribution." ], "strongest_contradictory_evidence": [ "A flexible loop is not an independently proved universal explanation; prospective baseline predictions are still required." ], "hsef_level_for_this_model": "Ε", "rationale": "Parkin/POLG interaction, protein-led import disruption, NCLX/USP30 rescue and variable PD complex-I subtypes support bounded reciprocal contribution. A flexible loop is not an independently proved universal explanation; prospective baseline predictions are still required." }, { "rank_in_tournament": 2, "model_id": "M2", "is_nominal": false, "name": "Selective vulnerability and permissive threshold", "core_claim": "Mitochondrial reserve and compartmental demand determine injury after defined stresses.", "explains_what_nominal_does_not": "Mitochondrial reserve and compartmental demand determine injury after defined stresses.", "strongest_supporting_evidence": [ "Ndufs2 functional compensation, mtDNA-copy maintenance and young-mutator resistance distinguish reserve from inevitable cell death." ], "strongest_contradictory_evidence": [ "Reserve biomarkers do not uniquely predict human onset or exclude protein-mediated injury." ], "hsef_level_for_this_model": "Ε", "rationale": "Ndufs2 functional compensation, mtDNA-copy maintenance and young-mutator resistance distinguish reserve from inevitable cell death. Reserve biomarkers do not uniquely predict human onset or exclude protein-mediated injury." }, { "rank_in_tournament": 3, "model_id": "M3", "is_nominal": false, "name": "Proteinopathy-first amplification", "core_claim": "Pathogenic proteins initiate organelle disruption and mitochondrial changes amplify pathology.", "explains_what_nominal_does_not": "Pathogenic proteins initiate organelle disruption and mitochondrial changes amplify pathology.", "strongest_supporting_evidence": [ "HTT repression, alpha-synuclein/TOM20 and SOD1/VDAC place proteins upstream in defined models." ], "strongest_contradictory_evidence": [ "Mitochondrial lesions can also generate protein pathology; this is not the sole route to every sporadic case." ], "hsef_level_for_this_model": "Ε", "rationale": "HTT repression, alpha-synuclein/TOM20 and SOD1/VDAC place proteins upstream in defined models. Mitochondrial lesions can also generate protein pathology; this is not the sole route to every sporadic case." }, { "rank_in_tournament": 4, "model_id": "M1", "is_nominal": true, "name": "Mitochondrial-first cascade", "core_claim": "Ordinary age-related mitochondrial failure initiates the common proteinopathies.", "explains_what_nominal_does_not": "Ordinary age-related mitochondrial failure initiates the common proteinopathies.", "strongest_supporting_evidence": [ "Cell-transfer and mitochondrial genetic lesions supply coherent mechanistic support." ], "strongest_contradictory_evidence": [ "Temporal human primacy and universal necessity are absent; physiological compensation and genetic HD contradict an unqualified common apex." ], "hsef_level_for_this_model": "Γ", "rationale": "Cell-transfer and mitochondrial genetic lesions supply coherent mechanistic support. Temporal human primacy and universal necessity are absent; physiological compensation and genetic HD contradict an unqualified common apex." }, { "rank_in_tournament": 5, "model_id": "M5", "is_nominal": false, "name": "Oxidative damage primacy", "core_claim": "ROS injury is the decisive common initiator rather than one downstream mediator.", "explains_what_nominal_does_not": "ROS injury is the decisive common initiator rather than one downstream mediator.", "strongest_supporting_evidence": [ "Redox perturbations and restricted edaravone clinical efficacy support relevance." ], "strongest_contradictory_evidence": [ "Antioxidant interventions are nonspecific, and neither initiation nor adequate-target universal failure is established." ], "hsef_level_for_this_model": "Γ", "rationale": "Redox perturbations and restricted edaravone clinical efficacy support relevance. Antioxidant interventions are nonspecific, and neither initiation nor adequate-target universal failure is established." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. Measure baseline mitochondrial reserve and protein pathology before onset, then selectively perturb each direction. The leading multi-hit model predicts interactions; the reserve-only rival predicts injury from reserve regardless of upstream protein state.", "study_separating_rank1_from_rank2": "Measure baseline mitochondrial reserve and protein pathology before onset, then selectively perturb each direction. The leading multi-hit model predicts interactions; the reserve-only rival predicts injury from reserve regardless of upstream protein state.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "17227870", "title": "Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons.", "citation": "Ekstrand MI, Terzioglu M, Galter D et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America. 2007.", "doi": "10.1073/pnas.0605208103", "pmcid": "PMC1783140", "url": "https://pubmed.ncbi.nlm.nih.gov/17227870/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17227870/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID17227870", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "DA-lineage Tfam deletion impairs respiratory-chain expression and produces adult progressive parkinsonism and neuron loss in MitoPark mice.", "what_it_does_not_show": "Forced broad mitochondrial transcription loss is not normal aging or proof of sporadic initiation; inclusions are not equivalent to Lewy proteinopathy; original body unavailable here.", "confounders_present": [ "Forced broad mitochondrial transcription loss is not normal aging or proof of sporadic initiation; inclusions are not equivalent to Lewy proteinopathy; original body unavailable here." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 2, "pmid": "34732887", "title": "Disruption of mitochondrial complex I induces progressive parkinsonism.", "citation": "González-Rodríguez P, Zampese E, Stout KA et al. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature. 2021.", "doi": "10.1038/s41586-021-04059-0", "pmcid": "PMC9189968", "url": "https://pubmed.ncbi.nlm.nih.gov/34732887/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34732887/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID35149834" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID34732887", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Loss of MCI induces metabolic reprogramming:paragraph0, 0:Loss of MCI induces metabolic reprogramming:paragraph1, 0:Loss of MCI induces metabolic reprogramming:paragraph2, 1:Early axonal dysfunction after Ndufs2 deletion:paragraph0, 2:Somatodendritic shift after Ndufs2 deletion:paragraph0, 2:Somatodendritic shift after Ndufs2 deletion:paragraph1, 4:Nigral determinants of motor disability:paragraph2, 4:Nigral determinants of motor disability:paragraph3, 4:Nigral determinants of motor disability:paragraph4. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M2" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Ndufs2 conditional deletion causes progressive dopamine dysfunction with glycolytic compensation; original Results retain retrogradely labelled cell bodies at P60 despite marker downregulation.", "what_it_does_not_show": "This developmental lineage deletion establishes functional parkinsonism, not early neuron death; retained somatic integrity limits marker-based degeneration claims; linked erratum details unexamined.", "confounders_present": [ "This developmental lineage deletion establishes functional parkinsonism, not early neuron death; retained somatic integrity limits marker-based degeneration claims; linked erratum details unexamined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 3, "pmid": "16604072", "title": "Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons.", "citation": "Kraytsberg Y, Kudryavtseva E, McKee AC et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nature genetics. 2006.", "doi": "10.1038/ng1778", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16604072/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16604072/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID16604072", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Single aged substantia-nigra neurons contain clonally expanded mtDNA deletions associated with respiratory deficiency.", "what_it_does_not_show": "Postmortem functional association lacks deletion-selective manipulation, pre-onset order or tracked neuronal fate.", "confounders_present": [ "Postmortem functional association lacks deletion-selective manipulation, pre-onset order or tracked neuronal fate." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 4, "pmid": "16604074", "title": "High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease.", "citation": "Bender A, Krishnan KJ, Morris CM et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nature genetics. 2006.", "doi": "10.1038/ng1769", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16604074/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16604074/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID16604074", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "High mtDNA deletion burdens accompany respiratory-chain deficiency in aged and PD substantia nigra.", "what_it_does_not_show": "Aged controls also carry high burdens; lesion presence does not establish differential death or etiological primacy.", "confounders_present": [ "Aged controls also carry high burdens; lesion presence does not establish differential death or etiological primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 5, "pmid": "26182419", "title": "Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress.", "citation": "Pickrell AM, Huang CH, Kennedy SR et al. Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress. Neuron. 2015.", "doi": "10.1016/j.neuron.2015.06.034", "pmcid": "PMC4803114", "url": "https://pubmed.ncbi.nlm.nih.gov/26182419/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26182419/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID26182419", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph5, 1:RESULTS:paragraph10, 1:RESULTS:paragraph11, 1:RESULTS:paragraph13. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4", "SC5" ], "favors_models": [ "M2", "M4" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Original Results confirm aged Parkin-null/POLG-mutator double mutants lose TH-positive and Nissl-counted neurons and show levodopa-responsive motor impairment; neither lesion alone does so.", "what_it_does_not_show": "Constitutive combined genetic stress models conditional vulnerability, not sporadic deletion primacy; Parkin loss does not increase total mutation burden and levodopa is symptomatic rescue.", "confounders_present": [ "Constitutive combined genetic stress models conditional vulnerability, not sporadic deletion primacy; Parkin loss does not increase total mutation burden and levodopa is symptomatic rescue." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 6, "pmid": "16672980", "title": "Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin.", "citation": "Park J, Lee SB, Lee S et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006.", "doi": "10.1038/nature04788", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16672980/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16672980/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID16672980", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Pink1-deficient flies show mitochondrial and muscular pathology plus dopaminergic degeneration; Parkin expression rescues mitochondrial and motor defects.", "what_it_does_not_show": "Constitutive fly loss and transgenic rescue do not establish spontaneous human disease or distinguish every Parkin function from bioenergetics.", "confounders_present": [ "Constitutive fly loss and transgenic rescue do not establish spontaneous human disease or distinguish every Parkin function from bioenergetics." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 7, "pmid": "16672981", "title": "Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin.", "citation": "Clark IE, Dodson MW, Jiang C et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006.", "doi": "10.1038/nature04779", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16672981/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16672981/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID16672981", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Independent Pink1 fly experiments link mitochondrial dysfunction and muscle degeneration to a Parkin-responsive pathway.", "what_it_does_not_show": "The abstract emphasizes muscle and fertility; it cannot be credited as a distinct mammalian neuronal-survival experiment or evidence of sporadic primacy.", "confounders_present": [ "The abstract emphasizes muscle and fertility; it cannot be credited as a distinct mammalian neuronal-survival experiment or evidence of sporadic primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 8, "pmid": "27874000", "title": "Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease.", "citation": "Dölle C, Flønes I, Nido GS et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nature communications. 2016.", "doi": "10.1038/ncomms13548", "pmcid": "PMC5121427", "url": "https://pubmed.ncbi.nlm.nih.gov/27874000/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27874000/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID27874000", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Aged controls compensate deletion burden with increased mtDNA copy number; this maintenance of wild-type mtDNA is deficient in PD neurons.", "what_it_does_not_show": "Cross-sectional surviving cells do not resolve whether failed compensation precedes disease or follows proteinopathy.", "confounders_present": [ "Cross-sectional surviving cells do not resolve whether failed compensation precedes disease or follows proteinopathy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 9, "pmid": "25450660", "title": "Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice.", "citation": "Dai Y, Clark J, Zheng K et al. Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice. Neurotoxicology and teratology. 2014.", "doi": "10.1016/j.ntt.2014.10.004", "pmcid": "PMC4293310", "url": "https://pubmed.ncbi.nlm.nih.gov/25450660/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25450660/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID25450660", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Young POLG-mutator mice do not show increased MPTP vulnerability by dopamine-neuron counts and striatal dopamine measurements.", "what_it_does_not_show": "This is an age- and insult-specific negative result, not exclusion of late-life combined Parkin/mutation pathology.", "confounders_present": [ "This is an age- and insult-specific negative result, not exclusion of late-life combined Parkin/mutation pathology." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 10, "pmid": "21376232", "title": "PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease.", "citation": "Shin JH, Ko HS, Kang H et al. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell. 2011.", "doi": "10.1016/j.cell.2011.02.010", "pmcid": "PMC3063894", "url": "https://pubmed.ncbi.nlm.nih.gov/21376232/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21376232/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "Parkin-PARIS-platform", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph8, 1:RESULTS:paragraph9, 1:RESULTS:paragraph18, 1:RESULTS:paragraph19, 1:RESULTS:paragraph20, 1:RESULTS:paragraph22. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M2", "M4" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Original adult conditional Parkin-loss Results show PARIS/PGC-1alpha changes before progressive TH and Nissl neuron loss; PARIS knockdown attenuates that loss.", "what_it_does_not_show": "Germline Parkin deletion compensates; PGC-1alpha survival rescue is in PARIS overexpression rather than a selective human-ageing lesion; human tissue remains associative.", "confounders_present": [ "Germline Parkin deletion compensates; PGC-1alpha survival rescue is in PARIS overexpression rather than a selective human-ageing lesion; human tissue remains associative." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 11, "pmid": "26324925", "title": "Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration.", "citation": "Stevens DA, Lee Y, Kang HC et al. Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proceedings of the National Academy of Sciences of the United States of America. 2015.", "doi": "10.1073/pnas.1500624112", "pmcid": "PMC4577198", "url": "https://pubmed.ncbi.nlm.nih.gov/26324925/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26324925/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "Parkin-PARIS-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Adult Parkin knockout reduces mitochondrial mass; PARIS knockdown prevents mass changes and PARIS overexpression disrupts PGC-1alpha-dependent respiration.", "what_it_does_not_show": "The same PARIS/Parkin platform is a mechanistic extension rather than an independent sporadic initiation line; organelle markers do not independently prove cell death.", "confounders_present": [ "The same PARIS/Parkin platform is a mechanistic extension rather than an independent sporadic initiation line; organelle markers do not independently prove cell death." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 12, "pmid": "32795422", "title": "Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons.", "citation": "Kumar M, Acevedo-Cintrón J, Jhaldiyal A et al. Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. Stem cell reports. 2020.", "doi": "10.1016/j.stemcr.2020.07.013", "pmcid": "PMC7486221", "url": "https://pubmed.ncbi.nlm.nih.gov/32795422/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32795422/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "Parkin-PARIS-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "PARIS CRISPR knockdown restores biogenesis and mitochondrial function in PARKIN-deficient human dopamine neurons while mitophagy defects persist.", "what_it_does_not_show": "In-vitro genetic cells separate biogenesis from mitophagy but do not demonstrate organismal progression or sporadic upstream order.", "confounders_present": [ "In-vitro genetic cells separate biogenesis from mitophagy but do not demonstrate organismal progression or sporadic upstream order." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 13, "pmid": "32138754", "title": "PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.", "citation": "Pirooznia SK, Yuan C, Khan MR et al. PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. Molecular neurodegeneration. 2020.", "doi": "10.1186/s13024-020-00363-x", "pmcid": "PMC7057660", "url": "https://pubmed.ncbi.nlm.nih.gov/32138754/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32138754/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "Parkin-PARIS-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Fly PINK1/Parkin insufficiency produces PARIS-linked biogenesis deficits and TH-positive neuronal/motor changes reversed by pathway overexpression.", "what_it_does_not_show": "TH immunostaining alone may conflate identity and survival; constitutive and overexpression methods constrain inference; related PARIS biology shares failure modes.", "confounders_present": [ "TH immunostaining alone may conflate identity and survival; constitutive and overexpression methods constrain inference; related PARIS biology shares failure modes." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 14, "pmid": "34321320", "title": "PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease.", "citation": "Jo A, Lee Y, Kam TI et al. PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease. Science translational medicine. 2021.", "doi": "10.1126/scitranslmed.aax8891", "pmcid": "PMC9990146", "url": "https://pubmed.ncbi.nlm.nih.gov/34321320/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34321320/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "Parkin-PARIS-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Farnesol limits PARIS promoter repression and protects neuronal and behavioral phenotypes across adult Parkin-loss and artificial alpha-synuclein/PARIS settings.", "what_it_does_not_show": "Pharmacological specificity and constructed models restrict generalization; multiple models in one programme are not independent human etiological confirmation.", "confounders_present": [ "Pharmacological specificity and constructed models restrict generalization; multiple models in one programme are not independent human etiological confirmation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 15, "pmid": "34791217", "title": "Mouse midbrain dopaminergic neurons survive loss of the PD-associated mitochondrial protein CHCHD2.", "citation": "Nguyen MK, McAvoy K, Liao SC et al. Mouse midbrain dopaminergic neurons survive loss of the PD-associated mitochondrial protein CHCHD2. Human molecular genetics. 2022.", "doi": "10.1093/hmg/ddab329", "pmcid": "PMC9071413", "url": "https://pubmed.ncbi.nlm.nih.gov/34791217/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34791217/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID34791217", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "DA-specific, brain-wide and whole-body CHCHD2 loss preserve DA neurons and OXPHOS; double CHCHD2/CHCHD10 loss also preserves midbrain neurons.", "what_it_does_not_show": "Absence of loss-of-function pathology does not refute a pathogenic CHCHD2 gain-of-function mutation; gene identity alone cannot diagnose respiratory failure.", "confounders_present": [ "Absence of loss-of-function pathology does not refute a pathogenic CHCHD2 gain-of-function mutation; gene identity alone cannot diagnose respiratory failure." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 16, "pmid": "36322611", "title": "CHCHD2 p.Thr61Ile knock-in mice exhibit motor defects and neuropathological features of Parkinson's disease.", "citation": "Fan L, Zhang S, Li X et al. CHCHD2 p.Thr61Ile knock-in mice exhibit motor defects and neuropathological features of Parkinson's disease. Brain pathology (Zurich, Switzerland). 2023.", "doi": "10.1111/bpa.13124", "pmcid": "PMC10154378", "url": "https://pubmed.ncbi.nlm.nih.gov/36322611/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36322611/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID36322611", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Endogenous CHCHD2 T61I knock-in causes age-related motor deficits, DA loss, mitochondrial abnormalities and alpha-synuclein accumulation.", "what_it_does_not_show": "A familial pathogenic mutation with inferred IDE effects is not proof that ordinary bioenergetic decline initiates sporadic PD; direction requires temporal separation.", "confounders_present": [ "A familial pathogenic mutation with inferred IDE effects is not proof that ordinary bioenergetic decline initiates sporadic PD; direction requires temporal separation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 17, "pmid": "27280685", "title": "α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.", "citation": "Di Maio R, Barrett PJ, Hoffman EK et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Science translational medicine. 2016.", "doi": "10.1126/scitranslmed.aaf3634", "pmcid": "PMC5016095", "url": "https://pubmed.ncbi.nlm.nih.gov/27280685/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27280685/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID27280685", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [ "M3", "M4" ], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Modified alpha-synuclein inhibits TOM20-mediated import; endogenous alpha-synuclein lowering preserves import in a PD model and human tissue shows the interaction.", "what_it_does_not_show": "Protein-driven mitochondrial disruption provides a reverse-direction route; import or in-vitro TOM20 rescue alone is not human survival or initiation proof.", "confounders_present": [ "Protein-driven mitochondrial disruption provides a reverse-direction route; import or in-vitro TOM20 rescue alone is not human survival or initiation proof." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 18, "pmid": "39379975", "title": "α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease.", "citation": "Geibl FF, Henrich MT, Xie Z et al. α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease. Molecular neurodegeneration. 2024.", "doi": "10.1186/s13024-024-00756-2", "pmcid": "PMC11462807", "url": "https://pubmed.ncbi.nlm.nih.gov/39379975/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39379975/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "UpdateOf: PMID38168401" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID39379975", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Injected alpha-synuclein PFFs produce neuronal loss and mitochondrial ATP/redox abnormalities in vulnerable dopamine and cholinergic populations.", "what_it_does_not_show": "Forced seeding places protein pathology upstream experimentally; it cannot establish natural onset or turn a mitochondrial proximal mediator into the initiating cause.", "confounders_present": [ "Forced seeding places protein pathology upstream experimentally; it cannot establish natural onset or turn a mitochondrial proximal mediator into the initiating cause." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 19, "pmid": "38684731", "title": "Mitochondrial complex I deficiency stratifies idiopathic Parkinson's disease.", "citation": "Flønes IH, Toker L, Sandnes DA et al. Mitochondrial complex I deficiency stratifies idiopathic Parkinson's disease. Nature communications. 2024.", "doi": "10.1038/s41467-024-47867-4", "pmcid": "PMC11059185", "url": "https://pubmed.ncbi.nlm.nih.gov/38684731/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38684731/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID38684731", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Idiopathic PD stratifies by widespread neuronal complex-I deficiency, with distinct molecular and clinical profiles and deletion burden.", "what_it_does_not_show": "Postmortem subtype classification is not pre-onset causal identification; many cases lack extra-nigral impairment and outcome-defined strata cannot rescue a universal claim.", "confounders_present": [ "Postmortem subtype classification is not pre-onset causal identification; many cases lack extra-nigral impairment and outcome-defined strata cannot rescue a universal claim." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 20, "pmid": "39167658", "title": "Phosphoglycerate kinase is a central leverage point in Parkinson's disease-driven neuronal metabolic deficits.", "citation": "Kokotos AC, Antoniazzi AM, Unda SR et al. Phosphoglycerate kinase is a central leverage point in Parkinson's disease-driven neuronal metabolic deficits. Science advances. 2024.", "doi": "10.1126/sciadv.adn6016", "pmcid": "PMC11338267", "url": "https://pubmed.ncbi.nlm.nih.gov/39167658/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39167658/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "UpdateOf: PMID37873141" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID39167658", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Modest PGK1 augmentation improves neuronal ATP kinetics and synaptic function; viral expression protects dopamine axons from metabolic lesions.", "what_it_does_not_show": "Glycolytic support and axonal function are broader than mitochondrial respiration; induced lesions and marker endpoints do not prove neuronal survival in sporadic PD.", "confounders_present": [ "Glycolytic support and axonal function are broader than mitochondrial respiration; induced lesions and marker endpoints do not prove neuronal survival in sporadic PD." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 21, "pmid": "37957154", "title": "Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model.", "citation": "Fang TZ, Sun Y, Pearce AC et al. Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model. Nature communications. 2023.", "doi": "10.1038/s41467-023-42876-1", "pmcid": "PMC10643470", "url": "https://pubmed.ncbi.nlm.nih.gov/37957154/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37957154/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID37957154", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "USP30 genetic loss and a brain-penetrant inhibitor attenuate alpha-synuclein-induced DA loss and motor deficits while increasing mitophagy.", "what_it_does_not_show": "A protein-triggered model supports a modifiable downstream quality-control contribution; it does not establish mitochondrial-first onset in humans.", "confounders_present": [ "A protein-triggered model supports a modifiable downstream quality-control contribution; it does not establish mitochondrial-first onset in humans." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 22, "pmid": "41856111", "title": "Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson's disease models.", "citation": "Du S, Long Q, Zhou Y et al. Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson's disease models. Cell. 2026.", "doi": "10.1016/j.cell.2026.02.023", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/41856111/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41856111/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID42140184" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID41856111", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Encapsulated mitochondrial transfer rescues bioenergetics in patient cells and phenotypes in mitochondrial-disease mice, with neuronal/motor rescue in a PD model.", "what_it_does_not_show": "Organelle delivery is pleiotropic and induced-model specific; no human PD trajectory is established; linked correction details are unexamined.", "confounders_present": [ "Organelle delivery is pleiotropic and induced-model specific; no human PD trajectory is established; linked correction details are unexamined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 23, "pmid": "31316206", "title": "Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-/- mice.", "citation": "Matheoud D, Cannon T, Voisin A et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-/- mice. Nature. 2019.", "doi": "10.1038/s41586-019-1405-y", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31316206/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31316206/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID31316206", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Gram-negative infection in Pink1-null mice elicits mitochondrial-antigen CD8 responses, striatal varicosity loss and levodopa-responsive motor impairment.", "what_it_does_not_show": "The demonstrated phenotype is immune-context-dependent axonal dysfunction, not established nigral cell death or unconditional respiratory-loss sufficiency.", "confounders_present": [ "The demonstrated phenotype is immune-context-dependent axonal dysfunction, not established nigral cell death or unconditional respiratory-loss sufficiency." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 24, "pmid": "21269927", "title": "Rotenone, paraquat, and Parkinson's disease.", "citation": "Tanner CM, Kamel F, Ross GW et al. Rotenone, paraquat, and Parkinson's disease. Environmental health perspectives. 2011.", "doi": "10.1289/ehp.1002839", "pmcid": "PMC3114824", "url": "https://pubmed.ncbi.nlm.nih.gov/21269927/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21269927/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID21269927", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A nested agricultural case-control study links rotenone/paraquat exposure groups to diagnosed PD.", "what_it_does_not_show": "Recall, co-exposures and non-mitochondrial toxic actions prevent a selective instrument or proof that age-related respiration failure mediates onset.", "confounders_present": [ "Recall, co-exposures and non-mitochondrial toxic actions prevent a selective instrument or proof that age-related respiration failure mediates onset." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 25, "pmid": "39709505", "title": "BCKDK loss impairs mitochondrial Complex I activity and drives alpha-synuclein aggregation in models of Parkinson's disease.", "citation": "Jishi A, Hu D, Shang Y et al. BCKDK loss impairs mitochondrial Complex I activity and drives alpha-synuclein aggregation in models of Parkinson's disease. Acta neuropathologica communications. 2024.", "doi": "10.1186/s40478-024-01915-8", "pmcid": "PMC11662730", "url": "https://pubmed.ncbi.nlm.nih.gov/39709505/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39709505/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID39709505", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "BCKDK loss destabilizes complex I and promotes alpha-synuclein pathology; restoring BCKDK rescues respiration and partly restores patient-derived cell markers.", "what_it_does_not_show": "Stress-conditioned cellular rescue and postmortem associations do not establish spontaneous in-vivo neuronal loss or mitochondrial primacy.", "confounders_present": [ "Stress-conditioned cellular rescue and postmortem associations do not establish spontaneous in-vivo neuronal loss or mitochondrial primacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 26, "pmid": "25226871", "title": "Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study.", "citation": "Siuda J, Jasinska-Myga B, Boczarska-Jedynak M et al. Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study. Parkinsonism & related disorders. 2014.", "doi": "10.1016/j.parkreldis.2014.08.019", "pmcid": "PMC4253017", "url": "https://pubmed.ncbi.nlm.nih.gov/25226871/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25226871/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID25226871", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "natural experiment", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Two homozygous PINK1 Q456X relatives develop early PD with loss of kinase/Parkin-substrate function; heterozygous carriers remain unaffected.", "what_it_does_not_show": "Familial gene causality and peripheral fibroblast assays do not isolate bioenergetics from immune/quality-control actions or explain sporadic late-life disease.", "confounders_present": [ "Familial gene causality and peripheral fibroblast assays do not isolate bioenergetics from immune/quality-control actions or explain sporadic late-life disease." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 27, "pmid": "28153046", "title": "Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains.", "citation": "Wei W, Keogh MJ, Wilson I et al. Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta neuropathologica communications. 2017.", "doi": "10.1186/s40478-016-0404-6", "pmcid": "PMC5290662", "url": "https://pubmed.ncbi.nlm.nih.gov/28153046/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28153046/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID28228164" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID28153046", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Whole-mitochondrial sequencing of disease/control brains finds no major disease association for rare inherited or heteroplasmic point variants, with some copy-number differences.", "what_it_does_not_show": "Bulk tissue may miss single-cell deletion lesions; a point-mutation null cannot exclude deletion/compartment effects; linked erratum details unexamined.", "confounders_present": [ "Bulk tissue may miss single-cell deletion lesions; a point-mutation null cannot exclude deletion/compartment effects; linked erratum details unexamined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 28, "pmid": "17018277", "title": "Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.", "citation": "Cui L, Jeong H, Borovecki F et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006.", "doi": "10.1016/j.cell.2006.09.015", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17018277/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17018277/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID17018277", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice; PGC-1alpha expression rescues induced neuronal toxicity and protects transgenic striatum.", "what_it_does_not_show": "Mutant huntingtin represses PGC-1alpha upstream; global biogenesis loss and overexpression rescue support contribution within genetic HD, not sporadic mitochondrial initiation.", "confounders_present": [ "Mutant huntingtin represses PGC-1alpha upstream; global biogenesis loss and overexpression rescue support contribution within genetic HD, not sporadic mitochondrial initiation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 29, "pmid": "17055784", "title": "Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.", "citation": "Weydt P, Pineda VV, Torrence AE et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell metabolism. 2006.", "doi": "10.1016/j.cmet.2006.10.004", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/17055784/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17055784/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID17055784", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "HD mice show thermoregulatory, mitochondrial and PGC-1alpha target abnormalities; exogenous PGC-1alpha protects striatal cells from a mitochondrial toxin.", "what_it_does_not_show": "Brown-fat and toxin phenotypes do not independently prove endogenous striatal necessity or an etiological apex; huntingtin is the defined initiating mutation.", "confounders_present": [ "Brown-fat and toxin phenotypes do not independently prove endogenous striatal necessity or an etiological apex; huntingtin is the defined initiating mutation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 30, "pmid": "27008868", "title": "Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.", "citation": "Chandra A, Sharma A, Calingasan NY et al. Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease. Human molecular genetics. 2016.", "doi": "10.1093/hmg/ddw095", "pmcid": "PMC5081058", "url": "https://pubmed.ncbi.nlm.nih.gov/27008868/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27008868/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID27008868", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Bezafibrate restores biogenesis/antioxidant signatures and ameliorates motor and striatal pathology in full-length BACHD mice.", "what_it_does_not_show": "A pan-PPAR agonist is pleiotropic; benefits under mutant HTT do not identify biogenesis alone or reverse genetic upstream order.", "confounders_present": [ "A pan-PPAR agonist is pleiotropic; benefits under mutant HTT do not identify biogenesis alone or reverse genetic upstream order." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 31, "pmid": "30768179", "title": "Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites.", "citation": " et al. Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites. Human molecular genetics. 2020.", "doi": "10.1093/hmg/ddy430", "pmcid": "PMC7372552", "url": "https://pubmed.ncbi.nlm.nih.gov/30768179/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30768179/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "HD-iPSC-Consortium", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph9, 1:Results:paragraph11, 1:Results:paragraph14. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [ "M3", "M4" ], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Original Results show reduced ATP and spare glycolytic capacity with largely retained respiratory reserve; late glycolytic metabolites improve ATP and mutant-HTT neuron viability.", "what_it_does_not_show": "One long-repeat line has reduced maximal respiration; rescue in transfected mouse neurons differs from human-cell ATP rescue; small donor panels and artificial cultures limit generalization.", "confounders_present": [ "One long-repeat line has reduced maximal respiration; rescue in transfected mouse neurons differs from human-cell ATP rescue; small donor panels and artificial cultures limit generalization." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 32, "pmid": "7599213", "title": "Paucity of deleted mitochondrial DNAs in brain regions of Huntington's disease patients.", "citation": "Chen X, Bonilla E, Sciacco M et al. Paucity of deleted mitochondrial DNAs in brain regions of Huntington's disease patients. Biochimica et biophysica acta. 1995.", "doi": "10.1016/0925-4439(95)00032-y", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/7599213/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/7599213/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID7599213", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "The common mtDNA deletion is lower in two HD regions and unchanged in caudate, with similar respiratory-polypeptide staining.", "what_it_does_not_show": "Bulk gliosis can replace deletion-rich neurons and obscure vulnerability; this does not exclude every mitochondrial lesion.", "confounders_present": [ "Bulk gliosis can replace deletion-rich neurons and obscure vulnerability; this does not exclude every mitochondrial lesion." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 33, "pmid": "10441489", "title": "Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients.", "citation": "Swerdlow RH, Parks JK, Cassarino DS et al. Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Biochemical and biophysical research communications. 1999.", "doi": "10.1006/bbrc.1999.1095", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10441489/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10441489/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID10441489", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "HD platelet-mtDNA cybrids resemble control cybrids in respiration, oxidative stress and calcium assays.", "what_it_does_not_show": "The model excludes nuclear mutant HTT and tissue-specific effects; it constrains mitochondrial inheritance claims rather than all HD metabolic mechanisms.", "confounders_present": [ "The model excludes nuclear mutant HTT and tissue-specific effects; it constrains mitochondrial inheritance claims rather than all HD metabolic mechanisms." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 34, "pmid": "27131346", "title": "Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease.", "citation": "Hamilton J, Pellman JJ, Brustovetsky T et al. Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease. Human molecular genetics. 2016.", "doi": "10.1093/hmg/ddw133", "pmcid": "PMC5181640", "url": "https://pubmed.ncbi.nlm.nih.gov/27131346/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27131346/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID27131346", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Isolated synaptic/non-synaptic mitochondria and R6/2 striatal cultures show retained respiration, ATP and calcium handling.", "what_it_does_not_show": "Age, preparation and fragment-model conditions bound this negative result; isolated organelles can omit intact-neuron interactions.", "confounders_present": [ "Age, preparation and fragment-model conditions bound this negative result; isolated organelles can omit intact-neuron interactions." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 35, "pmid": "18721135", "title": "Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice.", "citation": "Oláh J, Klivényi P, Gardián G et al. Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. The FEBS journal. 2008.", "doi": "10.1111/j.1742-4658.2008.06612.x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/18721135/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18721135/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID18721135", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Affected HD-model brain tissue has increased glycolytic flux and ATP with altered enzyme activity and a fitted metabolic model.", "what_it_does_not_show": "Whole-tissue averages and partially predictive kinetic modelling do not establish neuronal ATP sufficiency or validate the proposed enzyme-channeling explanation.", "confounders_present": [ "Whole-tissue averages and partially predictive kinetic modelling do not establish neuronal ATP sufficiency or validate the proposed enzyme-channeling explanation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 36, "pmid": "32821928", "title": "Mutant huntingtin does not cross the mitochondrial outer membrane.", "citation": "Hamilton J, Brustovetsky T, Khanna R et al. Mutant huntingtin does not cross the mitochondrial outer membrane. Human molecular genetics. 2020.", "doi": "10.1093/hmg/ddaa185", "pmcid": "PMC7566381", "url": "https://pubmed.ncbi.nlm.nih.gov/32821928/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32821928/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID32821928", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Protease/alkali localization and respiratory assays place mutant HTT outside the mitochondrial outer membrane with no TIM23 import deficit in the examined preparations.", "what_it_does_not_show": "This challenges a specific import route, not every HTT-mitochondrial interaction or stage of HD; postmortem and isolation constraints persist.", "confounders_present": [ "This challenges a specific import route, not every HTT-mitochondrial interaction or stage of HD; postmortem and isolation constraints persist." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 37, "pmid": "22589246", "title": "A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset.", "citation": "Soyal SM, Felder TK, Auer S et al. A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Human molecular genetics. 2012.", "doi": "10.1093/hmg/dds177", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/22589246/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22589246/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID22589246", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Brain-specific PPARGC1A isoforms and regional haplotypes associate with HD onset age and show neuronal promoter activity.", "what_it_does_not_show": "Association of a broad regulatory locus is not a selective causal instrument for mitochondrial biogenesis or proof of primary initiation.", "confounders_present": [ "Association of a broad regulatory locus is not a selective causal instrument for mitochondrial biogenesis or proof of primary initiation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 38, "pmid": "18806802", "title": "Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease.", "citation": "Du H, Guo L, Fang F et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nature medicine. 2008.", "doi": "10.1038/nm.1868", "pmcid": "PMC2789841", "url": "https://pubmed.ncbi.nlm.nih.gov/18806802/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18806802/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID18806802", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Cyclophilin-D deletion protects mitochondrial calcium handling and neuronal stress responses while improving cognition and synaptic function in an amyloid model.", "what_it_does_not_show": "A-beta acts upstream of pore stress; lifelong knockout and model cognition do not establish sporadic onset or clinical disease modification.", "confounders_present": [ "A-beta acts upstream of pore stress; lifelong knockout and model cognition do not establish sporadic onset or clinical disease modification." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 39, "pmid": "38146639", "title": "New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease.", "citation": "Samanta S, Akhter F, Roy A et al. New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease. Brain : a journal of neurology. 2024.", "doi": "10.1093/brain/awad432", "pmcid": "PMC11484516", "url": "https://pubmed.ncbi.nlm.nih.gov/38146639/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38146639/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID38146639", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Ebselen/CypD blockade improves bioenergetics in sporadic AD cybrids and cognition, synaptic/inflammatory phenotypes in AD mice.", "what_it_does_not_show": "Ebselen has additional redox actions and induced-model benefits; no clinical trajectory or unique upstream cause is shown.", "confounders_present": [ "Ebselen has additional redox actions and induced-model benefits; no clinical trajectory or unique upstream cause is shown." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 40, "pmid": "31467276", "title": "Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease.", "citation": "Jadiya P, Kolmetzky DW, Tomar D et al. Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. Nature communications. 2019.", "doi": "10.1038/s41467-019-11813-6", "pmcid": "PMC6715724", "url": "https://pubmed.ncbi.nlm.nih.gov/31467276/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31467276/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "NCLX-calcium-platform", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph3, 1:Results:paragraph7, 1:Results:paragraph9, 1:Results:paragraph14. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M2", "M4" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Original NCLX deletion accelerates 3xTg-AD pathology/cognitive decline; regulated early postnatal NCLX expression preserves cognition and calcium handling with activity controls.", "what_it_does_not_show": "The rescue starts at four weeks, before disease, rather than reversing established dementia; 3xTg mutations and a roughly twofold transgene are not sporadic etiological proof.", "confounders_present": [ "The rescue starts at four weeks, before disease, rather than reversing established dementia; 3xTg mutations and a roughly twofold transgene are not sporadic etiological proof." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 41, "pmid": "36936788", "title": "Neuronal loss of NCLX-dependent mitochondrial calcium efflux mediates age-associated cognitive decline.", "citation": "Jadiya P, Cohen HM, Kolmetzky DW et al. Neuronal loss of NCLX-dependent mitochondrial calcium efflux mediates age-associated cognitive decline. iScience. 2023.", "doi": "10.1016/j.isci.2023.106296", "pmcid": "PMC10014305", "url": "https://pubmed.ncbi.nlm.nih.gov/36936788/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36936788/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "NCLX-calcium-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Neuronal NCLX loss alone induces age-related memory deficits, mild protein pathology and cell-death indicators without pre-existing amyloid/tau mutations.", "what_it_does_not_show": "A severe engineered efflux lesion and indications of death are not normal aging or proof of human universal initiation.", "confounders_present": [ "A severe engineered efflux lesion and indications of death are not normal aging or proof of human universal initiation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 42, "pmid": "42174122", "title": "Genetic ablation of neuronal mitochondrial calcium uptake impedes Alzheimer's disease progression.", "citation": "Jadiya P, Berezhnaya E, Kolmetzky DW et al. Genetic ablation of neuronal mitochondrial calcium uptake impedes Alzheimer's disease progression. The EMBO journal. 2026.", "doi": "10.1038/s44318-026-00809-w", "pmcid": "PMC13324160", "url": "https://pubmed.ncbi.nlm.nih.gov/42174122/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42174122/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "UpdateOf: PMID37904949" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "NCLX-calcium-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Conditional neuronal MCU loss reduces pathology and cognitive dysfunction in 3xTg-AD with autophagic and mitochondrial preservation.", "what_it_does_not_show": "Protection in a familial transgenic setting supports calcium dependence; the corresponding preprint is the same study, not independent replication or human disease modification.", "confounders_present": [ "Protection in a familial transgenic setting supports calcium dependence; the corresponding preprint is the same study, not independent replication or human disease modification." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 43, "pmid": "9339668", "title": "Cybrids in Alzheimer's disease: a cellular model of the disease?", "citation": "Swerdlow RH, Parks JK, Cassarino DS et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology. 1997.", "doi": "10.1212/wnl.49.4.918", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/9339668/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/9339668/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "AD-cybrid-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "AD platelet-mtDNA cybrids display reduced COX activity and increased ROS/scavenging activity in a standardized nuclear background.", "what_it_does_not_show": "Transfer into mtDNA-depleted tumor cells is artificial; the abstract infers mutations without identifying a causal variant or establishing prediagnostic neuronal onset.", "confounders_present": [ "Transfer into mtDNA-depleted tumor cells is artificial; the abstract infers mutations without identifying a causal variant or establishing prediagnostic neuronal onset." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 44, "pmid": "10939564", "title": "Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways.", "citation": "Khan SM, Cassarino DS, Abramova NN et al. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Annals of neurology. 2000.", "doi": "", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10939564/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10939564/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "AD-cybrid-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "AD cybrids show mitochondrial depolarization, caspase/A-beta changes and pharmacological modulation of A-beta secretion.", "what_it_does_not_show": "Selected cell lines and broad antioxidants/caspase inhibitors cannot establish primary in-vivo disease onset or unique mtDNA causality.", "confounders_present": [ "Selected cell lines and broad antioxidants/caspase inhibitors cannot establish primary in-vivo disease onset or unique mtDNA causality." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 45, "pmid": "22746213", "title": "Prodromal metabolic phenotype in MCI cybrids: implications for Alzheimer's disease.", "citation": "Silva DF, Santana I, Esteves AR et al. Prodromal metabolic phenotype in MCI cybrids: implications for Alzheimer's disease. Current Alzheimer research. 2013.", "doi": "10.2174/1567205011310020008", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/22746213/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22746213/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "AD-cybrid-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "MCI platelet-mtDNA cybrids show COX and oxidative-stress deficits and AD cybrids contain increased mitochondrial A-beta.", "what_it_does_not_show": "MCI is not pathology-free or necessarily pre-amyloid; cross-sectional transfer cannot prove mitochondrial change precedes proteinopathy in donors.", "confounders_present": [ "MCI is not pathology-free or necessarily pre-amyloid; cross-sectional transfer cannot prove mitochondrial change precedes proteinopathy in donors." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 46, "pmid": "10051601", "title": "Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease.", "citation": "Ito S, Ohta S, Nishimaki K et al. Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 1999.", "doi": "10.1073/pnas.96.5.2099", "pmcid": "PMC26743", "url": "https://pubmed.ncbi.nlm.nih.gov/10051601/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/10051601/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID10051601", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "AD platelet and brain-synaptosome mtDNA restores respiration similarly to age-matched controls in HeLa cybrids.", "what_it_does_not_show": "Different nuclear background and cell selection could alter sensitivity; the null contradicts universal transferable respiratory failure without excluding brain-specific interactions.", "confounders_present": [ "Different nuclear background and cell selection could alter sensitivity; the null contradicts universal transferable respiratory failure without excluding brain-specific interactions." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 47, "pmid": "32804126", "title": "Mitochondrial DNA Manipulations Affect Tau Oligomerization.", "citation": "Weidling IW, Wilkins HM, Koppel SJ et al. Mitochondrial DNA Manipulations Affect Tau Oligomerization. Journal of Alzheimer's disease : JAD. 2020.", "doi": "10.3233/JAD-200286", "pmcid": "PMC7962146", "url": "https://pubmed.ncbi.nlm.nih.gov/32804126/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32804126/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "AD-cybrid-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Acute/chronic mtDNA depletion and AD cybrid transfer increase tau oligomers in SH-SY5Y cells.", "what_it_does_not_show": "Ethidium-bromide stress, rho-zero adaptation and common transformed-cell platforms share failure modes; no human onset or neuronal fate is demonstrated.", "confounders_present": [ "Ethidium-bromide stress, rho-zero adaptation and common transformed-cell platforms share failure modes; no human onset or neuronal fate is demonstrated." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 48, "pmid": "40596736", "title": "Mitochondrial DNA affects tau phosphorylation in aging and Alzheimer's disease.", "citation": "Kemna RE, Kueck PJ, Honea R et al. Mitochondrial DNA affects tau phosphorylation in aging and Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.", "doi": "10.1002/alz.70390", "pmcid": "PMC12213451", "url": "https://pubmed.ncbi.nlm.nih.gov/40596736/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40596736/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "AD-cybrid-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "MCI/AD donor-mtDNA cybrids show altered tau phosphorylation and proteomes, correlating with donor plasma, cognition and morphology.", "what_it_does_not_show": "Constructed cells and cross-sectional donor correlations do not track causal onset or selective mitochondrial disease prevention.", "confounders_present": [ "Constructed cells and cross-sectional donor correlations do not track causal onset or selective mitochondrial disease prevention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 49, "pmid": "34522215", "title": "Alzheimer's disease-causing presenilin-1 mutations have deleterious effects on mitochondrial function.", "citation": "Han J, Park H, Maharana C et al. Alzheimer's disease-causing presenilin-1 mutations have deleterious effects on mitochondrial function. Theranostics. 2021.", "doi": "10.7150/thno.59776", "pmcid": "PMC8419044", "url": "https://pubmed.ncbi.nlm.nih.gov/34522215/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34522215/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID34522215", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Induced familial PS1 mutations disturb mitochondrial/MAM physiology; ATL2 lowering corrects abnormal contacts in cells.", "what_it_does_not_show": "Genetically determined protein changes are upstream in this design; morphology rescue and familial cell lines do not establish mitochondrial primacy in sporadic AD.", "confounders_present": [ "Genetically determined protein changes are upstream in this design; morphology rescue and familial cell lines do not establish mitochondrial primacy in sporadic AD." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 50, "pmid": "37777962", "title": "ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes.", "citation": "Lee H, Cho S, Kim MJ et al. ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes. Cell reports. 2023.", "doi": "10.1016/j.celrep.2023.113183", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37777962/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37777962/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID37777962", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Isogenic APOE4 astrocytes show lysosomal cholesterol retention and respiratory defects rescued by cholesterol depletion.", "what_it_does_not_show": "The cellular pathway is genotype/lysosome-led; no human neuronal trajectory or exclusive respiration-mediated risk is established.", "confounders_present": [ "The cellular pathway is genotype/lysosome-led; no human neuronal trajectory or exclusive respiration-mediated risk is established." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 51, "pmid": "38539014", "title": "TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models.", "citation": "Wilson EN, Wang C, Swarovski MS et al. TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models. Nature neuroscience. 2024.", "doi": "10.1038/s41593-024-01610-w", "pmcid": "PMC11102654", "url": "https://pubmed.ncbi.nlm.nih.gov/38539014/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38539014/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID38539014", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Trem1 loss preserves metabolic, inflammatory and memory phenotypes in ageing and amyloid mice; postmortem expression tracks AD severity.", "what_it_does_not_show": "A myeloid inflammatory intervention is not selective neuronal mitochondrial restoration, and amyloid-linked effects do not identify the initial sporadic event.", "confounders_present": [ "A myeloid inflammatory intervention is not selective neuronal mitochondrial restoration, and amyloid-linked effects do not identify the initial sporadic event." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 52, "pmid": "23486940", "title": "Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis.", "citation": "Parone PA, Da Cruz S, Han JS et al. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013.", "doi": "10.1523/JNEUROSCI.1119-12.2013", "pmcid": "PMC3711648", "url": "https://pubmed.ncbi.nlm.nih.gov/23486940/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23486940/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID23486940", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M2", "M4" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "CypD deletion improves calcium buffering, ATP, morphology and motor-neuron survival across three SOD1 mutants without improving denervation, progression or lifespan.", "what_it_does_not_show": "This is an engaged genetic dissociation between soma preservation and fatal paralysis; it bounds the pore mechanism, not every mitochondrial process or human sporadic ALS.", "confounders_present": [ "This is an engaged genetic dissociation between soma preservation and fatal paralysis; it bounds the pore mechanism, not every mitochondrial process or human sporadic ALS." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 53, "pmid": "19272377", "title": "The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice.", "citation": "Martin LJ, Gertz B, Pan Y et al. The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Experimental neurology. 2009.", "doi": "10.1016/j.expneurol.2009.02.015", "pmcid": "PMC2710399", "url": "https://pubmed.ncbi.nlm.nih.gov/19272377/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19272377/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID19272377", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "CypD reduction delays onset and extends lifespan in G93A-SOD1 mice with sex- and expression-dependent patterns.", "what_it_does_not_show": "Later multi-mutant experiments fail to reproduce disease-trajectory benefit despite engagement; model/background discrepancies remain unresolved.", "confounders_present": [ "Later multi-mutant experiments fail to reproduce disease-trajectory benefit despite engagement; model/background discrepancies remain unresolved." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 54, "pmid": "33031745", "title": "TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS.", "citation": "Yu CH, Davidson S, Harapas CR et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020.", "doi": "10.1016/j.cell.2020.09.020", "pmcid": "PMC7599077", "url": "https://pubmed.ncbi.nlm.nih.gov/33031745/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33031745/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID33031745", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "TDP-43 releases mitochondrial DNA and cGAS/STING suppression prevents downstream inflammatory signalling in cells and mutant mice.", "what_it_does_not_show": "TDP-43 is upstream experimentally; cytokine suppression and patient cGAMP do not establish mitochondrial-first disease or restored human function.", "confounders_present": [ "TDP-43 is upstream experimentally; cytokine suppression and patient cGAMP do not establish mitochondrial-first disease or restored human function." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 55, "pmid": "40069360", "title": "Mitochondrial respiratory complex IV deficiency recapitulates amyotrophic lateral sclerosis.", "citation": "Cheng M, Lu D, Li K et al. Mitochondrial respiratory complex IV deficiency recapitulates amyotrophic lateral sclerosis. Nature neuroscience. 2025.", "doi": "10.1038/s41593-025-01896-4", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40069360/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40069360/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID40119207" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID40069360", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Targeted mitochondrial complex-IV mutations in rat neurons induce TDP-43 redistribution, selective motor-neuron loss and paralysis.", "what_it_does_not_show": "Engineered sufficiency does not identify spontaneous sALS initiation; correction details unexamined and reported human-deficiency prevalence is not independently audited here.", "confounders_present": [ "Engineered sufficiency does not identify spontaneous sALS initiation; correction details unexamined and reported human-deficiency prevalence is not independently audited here." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 56, "pmid": "20797535", "title": "Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS.", "citation": "Israelson A, Arbel N, Da Cruz S et al. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron. 2010.", "doi": "10.1016/j.neuron.2010.07.019", "pmcid": "PMC2941987", "url": "https://pubmed.ncbi.nlm.nih.gov/20797535/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20797535/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID20797535", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Misfolded SOD1 inhibits VDAC1 conductance; VDAC1 reduction accelerates fatal paralysis in mutant-SOD1 mice.", "what_it_does_not_show": "This places protein toxicity before mitochondrial impairment and tests a familial interaction, not a universal mitochondrial initiator.", "confounders_present": [ "This places protein toxicity before mitochondrial impairment and tests a familial interaction, not a universal mitochondrial initiator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 57, "pmid": "26074815", "title": "Miro1 deficiency in amyotrophic lateral sclerosis.", "citation": "Zhang F, Wang W, Siedlak SL et al. Miro1 deficiency in amyotrophic lateral sclerosis. Frontiers in aging neuroscience. 2015.", "doi": "10.3389/fnagi.2015.00100", "pmcid": "PMC4443026", "url": "https://pubmed.ncbi.nlm.nih.gov/26074815/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26074815/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID26074815", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "ALS tissue/models show reduced Miro1 and glutamate challenge lowers Miro1 in motor neurons.", "what_it_does_not_show": "Expression and excitotoxic challenge support a downstream transport route; selective transport rescue with survival is absent from the examined abstract.", "confounders_present": [ "Expression and excitotoxic challenge support a downstream transport route; selective transport rescue with survival is absent from the examined abstract." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 58, "pmid": "28522181", "title": "Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.", "citation": " , et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 2017.", "doi": "10.1016/S1474-4422(17)30115-1", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/28522181/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28522181/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID28522181", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A prospective randomized trial using prior-study-defined early-ALS eligibility shows less 24-week ALSFRS-R decline with edaravone.", "what_it_does_not_show": "This establishes a restricted antioxidant clinical effect, not specific mitochondrial restoration or upstream cause; broad efficacy cannot be inferred from the selected cohort.", "confounders_present": [ "This establishes a restricted antioxidant clinical effect, not specific mitochondrial restoration or upstream cause; broad efficacy cannot be inferred from the selected cohort." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 59, "pmid": "35006266", "title": "Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.", "citation": "Witzel S, Maier A, Steinbach R et al. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA neurology. 2022.", "doi": "10.1001/jamaneurol.2021.4893", "pmcid": "PMC8749709", "url": "https://pubmed.ncbi.nlm.nih.gov/35006266/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35006266/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: PMID35696158" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "German-edaravone-cohort", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "A propensity-matched German long-term cohort finds no ALS progression, ventilation or survival advantage with edaravone, including eligibility-defined strata.", "what_it_does_not_show": "Treatment selection, residual confounding and exposure/completer selection prevent equivalence to randomized rejection; linked correction details unexamined.", "confounders_present": [ "Treatment selection, residual confounding and exposure/completer selection prevent equivalence to randomized rejection; linked correction details unexamined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 60, "pmid": "24067398", "title": "Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.", "citation": "Cudkowicz ME, van den Berg LH, Shefner JM et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. The Lancet. Neurology. 2013.", "doi": "10.1016/S1474-4422(13)70221-7", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24067398/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24067398/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID24067398", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "EMPOWER finds no dexpramipexole benefit on prespecified combined function/survival or separate efficacy endpoints.", "what_it_does_not_show": "A drug-regimen null with uncertain cellular target engagement cannot falsify every mitochondrial driver; an author-name correction is retained.", "confounders_present": [ "A drug-regimen null with uncertain cellular target engagement cannot falsify every mitochondrial driver; an author-name correction is retained." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 61, "pmid": "24447620", "title": "A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.", "citation": "Lenglet T, Lacomblez L, Abitbol JL et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. European journal of neurology. 2014.", "doi": "10.1111/ene.12344", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24447620/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24447620/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID24447620", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Olesoxime does not improve 18-month survival or sustained functional endpoints in riluzole-treated ALS.", "what_it_does_not_show": "Blood levels do not establish mitochondrial occupancy in target motor neurons; one transient secondary signal is not sustained disease modification.", "confounders_present": [ "Blood levels do not establish mitochondrial occupancy in target motor neurons; one transient secondary signal is not sustained disease modification." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 62, "pmid": "19743457", "title": "Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.", "citation": "Kaufmann P, Thompson JL, Levy G et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Annals of neurology. 2009.", "doi": "10.1002/ana.21743", "pmcid": "PMC2854625", "url": "https://pubmed.ncbi.nlm.nih.gov/19743457/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19743457/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID19743457", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "An adaptive CoQ10 ALS trial finds insufficient promise to proceed, with null secondary outcomes and sensitivity-dependent futility analyses.", "what_it_does_not_show": "A futility design is not a conventional superiority trial and does not establish adequate CNS mitochondrial engagement or mechanism absence.", "confounders_present": [ "A futility design is not a conventional superiority trial and does not establish adequate CNS mitochondrial engagement or mechanism absence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 63, "pmid": "25526593", "title": "Dexpramipexole is ineffective in two models of ALS related neurodegeneration.", "citation": "Vieira FG, LaDow E, Moreno A et al. Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PloS one. 2014.", "doi": "10.1371/journal.pone.0091608", "pmcid": "PMC4272269", "url": "https://pubmed.ncbi.nlm.nih.gov/25526593/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25526593/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID25526593", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC6" ], "favors_models": [], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "null", "what_it_shows": "Powered sibling-matched SOD1 screening and primary TDP-43 neurons show no substantial dexpramipexole survival/progression benefit at clinically comparable exposure.", "what_it_does_not_show": "Negative compound performance constrains translational rationale rather than every mitochondrial mechanism; a marginal single cellular indicator is retained.", "confounders_present": [ "Negative compound performance constrains translational rationale rather than every mitochondrial mechanism; a marginal single cellular indicator is retained." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 64, "pmid": "24664227", "title": "A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.", "citation": " , Beal MF, Oakes D et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA neurology. 2014.", "doi": "10.1001/jamaneurol.2014.131", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24664227/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24664227/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID24664227", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "High-dose CoQ10 in early PD reaches prespecified futility without clinical UPDRS benefit.", "what_it_does_not_show": "This treatment failure does not establish adequate neuronal engagement, timing or complete disproof of bioenergetic contribution.", "confounders_present": [ "This treatment failure does not establish adequate neuronal engagement, timing or complete disproof of bioenergetic contribution." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 65, "pmid": "25668262", "title": "Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.", "citation": " , Kieburtz K, Tilley BC et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015.", "doi": "10.1001/jama.2015.120", "pmcid": "PMC4349346", "url": "https://pubmed.ncbi.nlm.nih.gov/25668262/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25668262/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID25668262", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Long-term NET-PD creatine randomization is stopped for futility on a composite clinical progression outcome.", "what_it_does_not_show": "Energy buffering is broad and clinical treatment begins after diagnosis; neuronal mitochondrial correction is not demonstrated by this outcome.", "confounders_present": [ "Energy buffering is broad and clinical treatment begins after diagnosis; neuronal mitochondrial correction is not demonstrated by this outcome." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 66, "pmid": "32227247", "title": "Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.", "citation": " et al. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Annals of internal medicine. 2020.", "doi": "10.7326/M19-2534", "pmcid": "PMC7465126", "url": "https://pubmed.ncbi.nlm.nih.gov/32227247/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32227247/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID32227247", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "STEADY-PD III isradipine shows no three-year clinical progression benefit or secondary benefit.", "what_it_does_not_show": "The original abstract explicitly allows insufficient neuroprotective calcium-channel engagement; a universal engaged-mechanism null would overstate it.", "confounders_present": [ "The original abstract explicitly allows insufficient neuroprotective calcium-channel engagement; a universal engaged-mechanism null would overstate it." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 67, "pmid": "37246815", "title": "A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.", "citation": "Payne T, Appleby M, Buckley E et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2023.", "doi": "10.1002/mds.29450", "pmcid": "PMC10527073", "url": "https://pubmed.ncbi.nlm.nih.gov/37246815/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37246815/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID37246815", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph8, 2:Results:paragraph0, 2:Results:paragraph5, 2:Results:paragraph6, 2:Results:paragraph7, 2:Results:paragraph8. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Original UDCA Methods define safety as primary; Results show midbrain MRS energetic changes and a small sensor-gait signal, with null UPDRS group contrasts.", "what_it_does_not_show": "Thirty-one were randomized; MRS/gait subsets are smaller, secondary analyses unpowered and unadjusted for multiplicity; no established disease-modifying trajectory or cell-specific adequate engagement.", "confounders_present": [ "Thirty-one were randomized; MRS/gait subsets are smaller, secondary analyses unpowered and unadjusted for multiplicity; no established disease-modifying trajectory or cell-specific adequate engagement." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 68, "pmid": "35235774", "title": "The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.", "citation": "Brakedal B, Dölle C, Riemer F et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell metabolism. 2022.", "doi": "10.1016/j.cmet.2022.02.001", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/35235774/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35235774/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID35235774", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "NADPARK increases brain NAD variably and alters metabolic/inflammatory measures after 30 days.", "what_it_does_not_show": "Phase-I biomarker engagement and responder-associated clinical change do not establish progression; response-defined subsets cannot prospectively define scope.", "confounders_present": [ "Phase-I biomarker engagement and responder-associated clinical change do not establish progression; response-defined subsets cannot prospectively define scope." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 69, "pmid": "38016950", "title": "NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.", "citation": "Berven H, Kverneng S, Sheard E et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nature communications. 2023.", "doi": "10.1038/s41467-023-43514-6", "pmcid": "PMC10684646", "url": "https://pubmed.ncbi.nlm.nih.gov/38016950/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38016950/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID38016950", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "NR-SAFE supports short-term high-dose tolerability and blood NAD elevation in 20 patients.", "what_it_does_not_show": "Clinical change covaries with time since levodopa; four weeks and blood metabolites cannot establish mitochondrial disease modification.", "confounders_present": [ "Clinical change covaries with time since levodopa; four weeks and blood metabolites cannot establish mitochondrial disease modification." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 70, "pmid": "27913695", "title": "A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.", "citation": "McGarry A, McDermott M, Kieburtz K et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017.", "doi": "10.1212/WNL.0000000000003478", "pmcid": "PMC5224719", "url": "https://pubmed.ncbi.nlm.nih.gov/27913695/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27913695/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID27913695", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC6" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "2CARE high-dose CoQ10 in genetic HD is stopped for futility without functional-capacity or survival benefit.", "what_it_does_not_show": "The initiating HTT mutation is distinct from mitochondrial support; no adequate neuronal biochemical engagement is established by the null clinical outcome.", "confounders_present": [ "The initiating HTT mutation is distinct from mitochondrial support; no adequate neuronal biochemical engagement is established by the null clinical outcome." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 77, "verified": 77, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Β", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Pure association evidence — however large, however replicated — cannot exceed Β.", "specific_trigger": "Respiratory, mtDNA and metabolic abnormalities are reproducibly present, but variation by cell, disease and preparation is substantial. A descriptive tissue association is Β; it neither negates nor supplies causal perturbation.", "resulting_ceiling": "Β" }, { "subclaim_id": "SC4", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.", "specific_trigger": "Single-cell deletion burden has a plausible respiratory effect and healthy aged cells compensate, but no deletion-selective pre-onset manipulation tracks sporadic PD neuron fate. POLG/Parkin point-mutation interaction is not the same lesion. Combined mechanistic support gives Γ, not demonstrated deletion primacy.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC5", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.", "specific_trigger": "Mitochondrial-first engineered models and transferred cybrids coexist with protein-first import, permeability and immune pathways. No human temporal/counterfactual set establishes an etiological apex across sporadic AD, PD and ALS. Genetic HD starts with HTT, and mitochondria can modify its consequences. Γ applies to the broad initiating inference, not to the assembled narrow lesion causality.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC6", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.", "specific_trigger": "Large PD/ALS/HD drug trials are often null, but adequate neuronal engagement is not universally demonstrated. UDCA and NADPARK demonstrate human bioenergetic/metabolic changes without confirmed disease modification. Restricted edaravone functional benefit is not a selective mitochondrial restoration experiment. Mechanistically attributable clinical trajectory change remains Γ.", "resulting_ceiling": "Γ" } ], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Age-related mitochondrial bioenergetic failure is a primary upstream causal driver of neurodegeneration, initiating rather than following proteinopathies in sporadic Alzheimer’s, Parkinson’s, Huntington’s disease and ALS.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "Convergent endogenous neuronal lesions cross model-sufficiency boundaries as a set. That set is not re-capped because some supporting human studies are associative. The separate leap to ordinary sporadic etiological primacy remains Γ. HD loss/rescue crosses contextual contribution while the genetic HTT initiating event remains intact. Human biomarker engagement does not cross a clinical trajectory threshold.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "In vitro aggregation or seeding alone cannot establish sporadic onset; cybrid/tau effects are cellular.", "Droplet ageing is not relied on.", "Organoid toxicity without organismal follow-through is not used as the causal gate.", "Exogenous seeding alone limits PFF-to-sporadic initiation inference.", "Familial or severe engineered lesions are not transferred to ordinary ageing; endogenous model causality is adjudicated separately." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Respiratory, mtDNA and metabolic abnormalities are reproducibly present, but variation by cell, disease and preparation is substantial. A descriptive tissue association is Β; it neither negates nor supplies causal perturbation.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID17227870, PMID34732887, PMID26182419, PMID16672980, PMID16672981, PMID25450660, PMID21376232, PMID26324925, PMID32138754, PMID34321320, PMID34791217, PMID36322611, PMID37957154, PMID31316206, PMID18806802, PMID31467276, PMID36936788, PMID42174122, PMID38539014, PMID23486940, PMID19272377, PMID40069360, PMID20797535, PMID25526593", "gamma_hard_rules_triggered": [ "In vitro aggregation or seeding alone cannot establish sporadic onset; cybrid/tau effects are cellular.", "Droplet ageing is not relied on.", "Organoid toxicity without organismal follow-through is not used as the causal gate.", "Exogenous seeding alone limits PFF-to-sporadic initiation inference.", "Familial or severe engineered lesions are not transferred to ordinary ageing; endogenous model causality is adjudicated separately." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Tfam disruption, conditional adult Parkin/PARIS loss with Nissl-confirmed degeneration, combined POLG/Parkin stress and rat complex-IV editing provide distinct endogenous routes to disease-relevant injury. Model-level mitochondrial sufficiency reaches Ζ as a set. Ndufs2 primarily produces dysfunction with somatic survival and is not falsely counted as death. Contradictory pore effects and lesion severity block a uniform Η trajectory claim; sporadic human primacy is a separate subclaim.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID17018277, PMID27008868", "gamma_hard_rules_triggered": [ "In vitro aggregation or seeding alone cannot establish sporadic onset; cybrid/tau effects are cellular.", "Droplet ageing is not relied on.", "Organoid toxicity without organismal follow-through is not used as the causal gate.", "Exogenous seeding alone limits PFF-to-sporadic initiation inference.", "Familial or severe engineered lesions are not transferred to ordinary ageing; endogenous model causality is adjudicated separately." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Endogenous PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice and matched gain-of-function/PPAR approaches preserve phenotypes. This is genuine context-dependent biogenesis contribution (Ε), despite pleiotropy. Mutant HTT is upstream; donor-cell glycolytic and isolated-respiration counterexamples limit generalization and exclusive bioenergetic explanation.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID26182419, PMID25450660", "gamma_hard_rules_triggered": [ "In vitro aggregation or seeding alone cannot establish sporadic onset; cybrid/tau effects are cellular.", "Droplet ageing is not relied on.", "Organoid toxicity without organismal follow-through is not used as the causal gate.", "Exogenous seeding alone limits PFF-to-sporadic initiation inference.", "Familial or severe engineered lesions are not transferred to ordinary ageing; endogenous model causality is adjudicated separately." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Single-cell deletion burden has a plausible respiratory effect and healthy aged cells compensate, but no deletion-selective pre-onset manipulation tracks sporadic PD neuron fate. POLG/Parkin point-mutation interaction is not the same lesion. Combined mechanistic support gives Γ, not demonstrated deletion primacy.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC5", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID17227870, PMID34732887, PMID26182419, PMID16672980, PMID16672981, PMID21376232, PMID26324925, PMID32138754, PMID34321320, PMID34791217, PMID36322611, PMID37957154, PMID31316206, PMID17018277, PMID27008868, PMID18806802, PMID31467276, PMID36936788, PMID42174122, PMID38539014, PMID23486940, PMID19272377, PMID40069360, PMID20797535", "gamma_hard_rules_triggered": [ "In vitro aggregation or seeding alone cannot establish sporadic onset; cybrid/tau effects are cellular.", "Droplet ageing is not relied on.", "Organoid toxicity without organismal follow-through is not used as the causal gate.", "Exogenous seeding alone limits PFF-to-sporadic initiation inference.", "Familial or severe engineered lesions are not transferred to ordinary ageing; endogenous model causality is adjudicated separately." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Mitochondrial-first engineered models and transferred cybrids coexist with protein-first import, permeability and immune pathways. No human temporal/counterfactual set establishes an etiological apex across sporadic AD, PD and ALS. Genetic HD starts with HTT, and mitochondria can modify its consequences. Γ applies to the broad initiating inference, not to the assembled narrow lesion causality.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC6", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "PMID28522181, PMID24067398, PMID24447620, PMID19743457, PMID25526593, PMID24664227, PMID25668262, PMID32227247, PMID37246815, PMID35235774, PMID38016950, PMID27913695", "gamma_hard_rules_triggered": [ "In vitro aggregation or seeding alone cannot establish sporadic onset; cybrid/tau effects are cellular.", "Droplet ageing is not relied on.", "Organoid toxicity without organismal follow-through is not used as the causal gate.", "Exogenous seeding alone limits PFF-to-sporadic initiation inference.", "Familial or severe engineered lesions are not transferred to ordinary ageing; endogenous model causality is adjudicated separately." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Large PD/ALS/HD drug trials are often null, but adequate neuronal engagement is not universally demonstrated. UDCA and NADPARK demonstrate human bioenergetic/metabolic changes without confirmed disease modification. Restricted edaravone functional benefit is not a selective mitochondrial restoration experiment. Mechanistically attributable clinical trajectory change remains Γ.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "A descriptive association row cannot be raised by relabelling another causal claim; establish a separate intervention subclaim." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "yes", "supporting_evidence": [ "[1] DA-lineage Tfam deletion impairs respiratory-chain expression and produces adult progressive parkinsonism and neuron loss in MitoPark mice.", "[2] Ndufs2 conditional deletion causes progressive dopamine dysfunction with glycolytic compensation; original Results retain retrogradely labelled cell bodies at P60 despite marker downregulation.", "[5] Original Results confirm aged Parkin-null/POLG-mutator double mutants lose TH-positive and Nissl-counted neurons and show levodopa-responsive motor impairment; neither lesion alone does so.", "[6] Pink1-deficient flies show mitochondrial and muscular pathology plus dopaminergic degeneration; Parkin expression rescues mitochondrial and motor defects.", "[7] Independent Pink1 fly experiments link mitochondrial dysfunction and muscle degeneration to a Parkin-responsive pathway.", "[9] Young POLG-mutator mice do not show increased MPTP vulnerability by dopamine-neuron counts and striatal dopamine measurements.", "[10] Original adult conditional Parkin-loss Results show PARIS/PGC-1alpha changes before progressive TH and Nissl neuron loss; PARIS knockdown attenuates that loss.", "[11] Adult Parkin knockout reduces mitochondrial mass; PARIS knockdown prevents mass changes and PARIS overexpression disrupts PGC-1alpha-dependent respiration.", "[13] Fly PINK1/Parkin insufficiency produces PARIS-linked biogenesis deficits and TH-positive neuronal/motor changes reversed by pathway overexpression.", "[14] Farnesol limits PARIS promoter repression and protects neuronal and behavioral phenotypes across adult Parkin-loss and artificial alpha-synuclein/PARIS settings.", "[15] DA-specific, brain-wide and whole-body CHCHD2 loss preserve DA neurons and OXPHOS; double CHCHD2/CHCHD10 loss also preserves midbrain neurons.", "[16] Endogenous CHCHD2 T61I knock-in causes age-related motor deficits, DA loss, mitochondrial abnormalities and alpha-synuclein accumulation.", "[21] USP30 genetic loss and a brain-penetrant inhibitor attenuate alpha-synuclein-induced DA loss and motor deficits while increasing mitophagy.", "[23] Gram-negative infection in Pink1-null mice elicits mitochondrial-antigen CD8 responses, striatal varicosity loss and levodopa-responsive motor impairment.", "[38] Cyclophilin-D deletion protects mitochondrial calcium handling and neuronal stress responses while improving cognition and synaptic function in an amyloid model.", "[40] Original NCLX deletion accelerates 3xTg-AD pathology/cognitive decline; regulated early postnatal NCLX expression preserves cognition and calcium handling with activity controls.", "[41] Neuronal NCLX loss alone induces age-related memory deficits, mild protein pathology and cell-death indicators without pre-existing amyloid/tau mutations.", "[42] Conditional neuronal MCU loss reduces pathology and cognitive dysfunction in 3xTg-AD with autophagic and mitochondrial preservation.", "[51] Trem1 loss preserves metabolic, inflammatory and memory phenotypes in ageing and amyloid mice; postmortem expression tracks AD severity.", "[52] CypD deletion improves calcium buffering, ATP, morphology and motor-neuron survival across three SOD1 mutants without improving denervation, progression or lifespan.", "[53] CypD reduction delays onset and extends lifespan in G93A-SOD1 mice with sex- and expression-dependent patterns.", "[55] Targeted mitochondrial complex-IV mutations in rat neurons induce TDP-43 redistribution, selective motor-neuron loss and paralysis.", "[56] Misfolded SOD1 inhibits VDAC1 conductance; VDAC1 reduction accelerates fatal paralysis in mutant-SOD1 mice.", "[63] Powered sibling-matched SOD1 screening and primary TDP-43 neurons show no substantial dexpramipexole survival/progression benefit at clinically comparable exposure." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ε", "requirement_quoted": "Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.\n\nUse Ε when there is a real causal contribution, but generalization to the entire disease class fails.", "satisfied": "yes", "supporting_evidence": [ "[1] DA-lineage Tfam deletion impairs respiratory-chain expression and produces adult progressive parkinsonism and neuron loss in MitoPark mice.", "[2] Ndufs2 conditional deletion causes progressive dopamine dysfunction with glycolytic compensation; original Results retain retrogradely labelled cell bodies at P60 despite marker downregulation.", "[5] Original Results confirm aged Parkin-null/POLG-mutator double mutants lose TH-positive and Nissl-counted neurons and show levodopa-responsive motor impairment; neither lesion alone does so.", "[6] Pink1-deficient flies show mitochondrial and muscular pathology plus dopaminergic degeneration; Parkin expression rescues mitochondrial and motor defects.", "[7] Independent Pink1 fly experiments link mitochondrial dysfunction and muscle degeneration to a Parkin-responsive pathway.", "[9] Young POLG-mutator mice do not show increased MPTP vulnerability by dopamine-neuron counts and striatal dopamine measurements.", "[10] Original adult conditional Parkin-loss Results show PARIS/PGC-1alpha changes before progressive TH and Nissl neuron loss; PARIS knockdown attenuates that loss.", "[11] Adult Parkin knockout reduces mitochondrial mass; PARIS knockdown prevents mass changes and PARIS overexpression disrupts PGC-1alpha-dependent respiration.", "[13] Fly PINK1/Parkin insufficiency produces PARIS-linked biogenesis deficits and TH-positive neuronal/motor changes reversed by pathway overexpression.", "[14] Farnesol limits PARIS promoter repression and protects neuronal and behavioral phenotypes across adult Parkin-loss and artificial alpha-synuclein/PARIS settings.", "[15] DA-specific, brain-wide and whole-body CHCHD2 loss preserve DA neurons and OXPHOS; double CHCHD2/CHCHD10 loss also preserves midbrain neurons.", "[16] Endogenous CHCHD2 T61I knock-in causes age-related motor deficits, DA loss, mitochondrial abnormalities and alpha-synuclein accumulation.", "[21] USP30 genetic loss and a brain-penetrant inhibitor attenuate alpha-synuclein-induced DA loss and motor deficits while increasing mitophagy.", "[23] Gram-negative infection in Pink1-null mice elicits mitochondrial-antigen CD8 responses, striatal varicosity loss and levodopa-responsive motor impairment.", "[38] Cyclophilin-D deletion protects mitochondrial calcium handling and neuronal stress responses while improving cognition and synaptic function in an amyloid model.", "[40] Original NCLX deletion accelerates 3xTg-AD pathology/cognitive decline; regulated early postnatal NCLX expression preserves cognition and calcium handling with activity controls.", "[41] Neuronal NCLX loss alone induces age-related memory deficits, mild protein pathology and cell-death indicators without pre-existing amyloid/tau mutations.", "[42] Conditional neuronal MCU loss reduces pathology and cognitive dysfunction in 3xTg-AD with autophagic and mitochondrial preservation.", "[51] Trem1 loss preserves metabolic, inflammatory and memory phenotypes in ageing and amyloid mice; postmortem expression tracks AD severity.", "[52] CypD deletion improves calcium buffering, ATP, morphology and motor-neuron survival across three SOD1 mutants without improving denervation, progression or lifespan.", "[53] CypD reduction delays onset and extends lifespan in G93A-SOD1 mice with sex- and expression-dependent patterns.", "[55] Targeted mitochondrial complex-IV mutations in rat neurons induce TDP-43 redistribution, selective motor-neuron loss and paralysis.", "[56] Misfolded SOD1 inhibits VDAC1 conductance; VDAC1 reduction accelerates fatal paralysis in mutant-SOD1 mice.", "[63] Powered sibling-matched SOD1 screening and primary TDP-43 neurons show no substantial dexpramipexole survival/progression benefit at clinically comparable exposure." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Multiple independent causal lines in vivo\n- Replication across at least two relevant systems\n- Narrowing of major alternative models", "satisfied": "yes", "supporting_evidence": [ "[1] DA-lineage Tfam deletion impairs respiratory-chain expression and produces adult progressive parkinsonism and neuron loss in MitoPark mice.", "[2] Ndufs2 conditional deletion causes progressive dopamine dysfunction with glycolytic compensation; original Results retain retrogradely labelled cell bodies at P60 despite marker downregulation.", "[5] Original Results confirm aged Parkin-null/POLG-mutator double mutants lose TH-positive and Nissl-counted neurons and show levodopa-responsive motor impairment; neither lesion alone does so.", "[6] Pink1-deficient flies show mitochondrial and muscular pathology plus dopaminergic degeneration; Parkin expression rescues mitochondrial and motor defects.", "[7] Independent Pink1 fly experiments link mitochondrial dysfunction and muscle degeneration to a Parkin-responsive pathway.", "[9] Young POLG-mutator mice do not show increased MPTP vulnerability by dopamine-neuron counts and striatal dopamine measurements.", "[10] Original adult conditional Parkin-loss Results show PARIS/PGC-1alpha changes before progressive TH and Nissl neuron loss; PARIS knockdown attenuates that loss.", "[11] Adult Parkin knockout reduces mitochondrial mass; PARIS knockdown prevents mass changes and PARIS overexpression disrupts PGC-1alpha-dependent respiration.", "[13] Fly PINK1/Parkin insufficiency produces PARIS-linked biogenesis deficits and TH-positive neuronal/motor changes reversed by pathway overexpression.", "[14] Farnesol limits PARIS promoter repression and protects neuronal and behavioral phenotypes across adult Parkin-loss and artificial alpha-synuclein/PARIS settings.", "[15] DA-specific, brain-wide and whole-body CHCHD2 loss preserve DA neurons and OXPHOS; double CHCHD2/CHCHD10 loss also preserves midbrain neurons.", "[16] Endogenous CHCHD2 T61I knock-in causes age-related motor deficits, DA loss, mitochondrial abnormalities and alpha-synuclein accumulation.", "[21] USP30 genetic loss and a brain-penetrant inhibitor attenuate alpha-synuclein-induced DA loss and motor deficits while increasing mitophagy.", "[23] Gram-negative infection in Pink1-null mice elicits mitochondrial-antigen CD8 responses, striatal varicosity loss and levodopa-responsive motor impairment.", "[38] Cyclophilin-D deletion protects mitochondrial calcium handling and neuronal stress responses while improving cognition and synaptic function in an amyloid model.", "[40] Original NCLX deletion accelerates 3xTg-AD pathology/cognitive decline; regulated early postnatal NCLX expression preserves cognition and calcium handling with activity controls.", "[41] Neuronal NCLX loss alone induces age-related memory deficits, mild protein pathology and cell-death indicators without pre-existing amyloid/tau mutations.", "[42] Conditional neuronal MCU loss reduces pathology and cognitive dysfunction in 3xTg-AD with autophagic and mitochondrial preservation.", "[51] Trem1 loss preserves metabolic, inflammatory and memory phenotypes in ageing and amyloid mice; postmortem expression tracks AD severity.", "[52] CypD deletion improves calcium buffering, ATP, morphology and motor-neuron survival across three SOD1 mutants without improving denervation, progression or lifespan.", "[53] CypD reduction delays onset and extends lifespan in G93A-SOD1 mice with sex- and expression-dependent patterns.", "[55] Targeted mitochondrial complex-IV mutations in rat neurons induce TDP-43 redistribution, selective motor-neuron loss and paralysis.", "[56] Misfolded SOD1 inhibits VDAC1 conductance; VDAC1 reduction accelerates fatal paralysis in mutant-SOD1 mice.", "[63] Powered sibling-matched SOD1 screening and primary TDP-43 neurons show no substantial dexpramipexole survival/progression benefit at clinically comparable exposure." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Η", "requirement_quoted": "Requires:\n- Strong convergent causal evidence across systems\n- Intervention-sensitive change in trajectory\n- No major unresolved contradiction about whether the mechanism is upstream versus downstream", "satisfied": "no", "supporting_evidence": [ "[1] DA-lineage Tfam deletion impairs respiratory-chain expression and produces adult progressive parkinsonism and neuron loss in MitoPark mice.", "[2] Ndufs2 conditional deletion causes progressive dopamine dysfunction with glycolytic compensation; original Results retain retrogradely labelled cell bodies at P60 despite marker downregulation.", "[5] Original Results confirm aged Parkin-null/POLG-mutator double mutants lose TH-positive and Nissl-counted neurons and show levodopa-responsive motor impairment; neither lesion alone does so.", "[6] Pink1-deficient flies show mitochondrial and muscular pathology plus dopaminergic degeneration; Parkin expression rescues mitochondrial and motor defects.", "[7] Independent Pink1 fly experiments link mitochondrial dysfunction and muscle degeneration to a Parkin-responsive pathway.", "[9] Young POLG-mutator mice do not show increased MPTP vulnerability by dopamine-neuron counts and striatal dopamine measurements.", "[10] Original adult conditional Parkin-loss Results show PARIS/PGC-1alpha changes before progressive TH and Nissl neuron loss; PARIS knockdown attenuates that loss.", "[11] Adult Parkin knockout reduces mitochondrial mass; PARIS knockdown prevents mass changes and PARIS overexpression disrupts PGC-1alpha-dependent respiration.", "[13] Fly PINK1/Parkin insufficiency produces PARIS-linked biogenesis deficits and TH-positive neuronal/motor changes reversed by pathway overexpression.", "[14] Farnesol limits PARIS promoter repression and protects neuronal and behavioral phenotypes across adult Parkin-loss and artificial alpha-synuclein/PARIS settings.", "[15] DA-specific, brain-wide and whole-body CHCHD2 loss preserve DA neurons and OXPHOS; double CHCHD2/CHCHD10 loss also preserves midbrain neurons.", "[16] Endogenous CHCHD2 T61I knock-in causes age-related motor deficits, DA loss, mitochondrial abnormalities and alpha-synuclein accumulation.", "[21] USP30 genetic loss and a brain-penetrant inhibitor attenuate alpha-synuclein-induced DA loss and motor deficits while increasing mitophagy.", "[23] Gram-negative infection in Pink1-null mice elicits mitochondrial-antigen CD8 responses, striatal varicosity loss and levodopa-responsive motor impairment.", "[38] Cyclophilin-D deletion protects mitochondrial calcium handling and neuronal stress responses while improving cognition and synaptic function in an amyloid model.", "[40] Original NCLX deletion accelerates 3xTg-AD pathology/cognitive decline; regulated early postnatal NCLX expression preserves cognition and calcium handling with activity controls.", "[41] Neuronal NCLX loss alone induces age-related memory deficits, mild protein pathology and cell-death indicators without pre-existing amyloid/tau mutations.", "[42] Conditional neuronal MCU loss reduces pathology and cognitive dysfunction in 3xTg-AD with autophagic and mitochondrial preservation.", "[51] Trem1 loss preserves metabolic, inflammatory and memory phenotypes in ageing and amyloid mice; postmortem expression tracks AD severity.", "[52] CypD deletion improves calcium buffering, ATP, morphology and motor-neuron survival across three SOD1 mutants without improving denervation, progression or lifespan.", "[53] CypD reduction delays onset and extends lifespan in G93A-SOD1 mice with sex- and expression-dependent patterns.", "[55] Targeted mitochondrial complex-IV mutations in rat neurons induce TDP-43 redistribution, selective motor-neuron loss and paralysis.", "[56] Misfolded SOD1 inhibits VDAC1 conductance; VDAC1 reduction accelerates fatal paralysis in mutant-SOD1 mice.", "[63] Powered sibling-matched SOD1 screening and primary TDP-43 neurons show no substantial dexpramipexole survival/progression benefit at clinically comparable exposure." ], "what_would_cross_it": "Demonstrate intervention-sensitive disease trajectory in independently replicated physiological lesions with matched rescue, preserved general viability and reconciled pore/survival discrepancies." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "yes", "supporting_evidence": [ "[28] PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice; PGC-1alpha expression rescues induced neuronal toxicity and protects transgenic striatum.", "[30] Bezafibrate restores biogenesis/antioxidant signatures and ameliorates motor and striatal pathology in full-length BACHD mice." ], "what_would_cross_it": "" }, { "subclaim_id": "SC3", "threshold": "Ε", "requirement_quoted": "Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.\n\nUse Ε when there is a real causal contribution, but generalization to the entire disease class fails.", "satisfied": "yes", "supporting_evidence": [ "[28] PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice; PGC-1alpha expression rescues induced neuronal toxicity and protects transgenic striatum.", "[30] Bezafibrate restores biogenesis/antioxidant signatures and ameliorates motor and striatal pathology in full-length BACHD mice." ], "what_would_cross_it": "" }, { "subclaim_id": "SC3", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Multiple independent causal lines in vivo\n- Replication across at least two relevant systems\n- Narrowing of major alternative models", "satisfied": "no", "supporting_evidence": [ "[28] PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice; PGC-1alpha expression rescues induced neuronal toxicity and protects transgenic striatum.", "[30] Bezafibrate restores biogenesis/antioxidant signatures and ameliorates motor and striatal pathology in full-length BACHD mice." ], "what_would_cross_it": "Replicate selective endogenous biogenesis rescue in distinct HTT systems with survival rather than broad PPAR or ATP endpoints." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[5] Original Results confirm aged Parkin-null/POLG-mutator double mutants lose TH-positive and Nissl-counted neurons and show levodopa-responsive motor impairment; neither lesion alone does so.", "[9] Young POLG-mutator mice do not show increased MPTP vulnerability by dopamine-neuron counts and striatal dopamine measurements." ], "what_would_cross_it": "Selectively remove or reinstate defined somatic mtDNA deletions before disease in aged neurons and track cell fate with wild-type-copy compensation controls." }, { "subclaim_id": "SC5", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[1] DA-lineage Tfam deletion impairs respiratory-chain expression and produces adult progressive parkinsonism and neuron loss in MitoPark mice.", "[2] Ndufs2 conditional deletion causes progressive dopamine dysfunction with glycolytic compensation; original Results retain retrogradely labelled cell bodies at P60 despite marker downregulation.", "[5] Original Results confirm aged Parkin-null/POLG-mutator double mutants lose TH-positive and Nissl-counted neurons and show levodopa-responsive motor impairment; neither lesion alone does so.", "[6] Pink1-deficient flies show mitochondrial and muscular pathology plus dopaminergic degeneration; Parkin expression rescues mitochondrial and motor defects.", "[7] Independent Pink1 fly experiments link mitochondrial dysfunction and muscle degeneration to a Parkin-responsive pathway.", "[10] Original adult conditional Parkin-loss Results show PARIS/PGC-1alpha changes before progressive TH and Nissl neuron loss; PARIS knockdown attenuates that loss.", "[11] Adult Parkin knockout reduces mitochondrial mass; PARIS knockdown prevents mass changes and PARIS overexpression disrupts PGC-1alpha-dependent respiration.", "[13] Fly PINK1/Parkin insufficiency produces PARIS-linked biogenesis deficits and TH-positive neuronal/motor changes reversed by pathway overexpression.", "[14] Farnesol limits PARIS promoter repression and protects neuronal and behavioral phenotypes across adult Parkin-loss and artificial alpha-synuclein/PARIS settings.", "[15] DA-specific, brain-wide and whole-body CHCHD2 loss preserve DA neurons and OXPHOS; double CHCHD2/CHCHD10 loss also preserves midbrain neurons.", "[16] Endogenous CHCHD2 T61I knock-in causes age-related motor deficits, DA loss, mitochondrial abnormalities and alpha-synuclein accumulation.", "[21] USP30 genetic loss and a brain-penetrant inhibitor attenuate alpha-synuclein-induced DA loss and motor deficits while increasing mitophagy.", "[23] Gram-negative infection in Pink1-null mice elicits mitochondrial-antigen CD8 responses, striatal varicosity loss and levodopa-responsive motor impairment.", "[28] PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice; PGC-1alpha expression rescues induced neuronal toxicity and protects transgenic striatum.", "[30] Bezafibrate restores biogenesis/antioxidant signatures and ameliorates motor and striatal pathology in full-length BACHD mice.", "[38] Cyclophilin-D deletion protects mitochondrial calcium handling and neuronal stress responses while improving cognition and synaptic function in an amyloid model.", "[40] Original NCLX deletion accelerates 3xTg-AD pathology/cognitive decline; regulated early postnatal NCLX expression preserves cognition and calcium handling with activity controls.", "[41] Neuronal NCLX loss alone induces age-related memory deficits, mild protein pathology and cell-death indicators without pre-existing amyloid/tau mutations.", "[42] Conditional neuronal MCU loss reduces pathology and cognitive dysfunction in 3xTg-AD with autophagic and mitochondrial preservation.", "[51] Trem1 loss preserves metabolic, inflammatory and memory phenotypes in ageing and amyloid mice; postmortem expression tracks AD severity.", "[52] CypD deletion improves calcium buffering, ATP, morphology and motor-neuron survival across three SOD1 mutants without improving denervation, progression or lifespan.", "[53] CypD reduction delays onset and extends lifespan in G93A-SOD1 mice with sex- and expression-dependent patterns.", "[55] Targeted mitochondrial complex-IV mutations in rat neurons induce TDP-43 redistribution, selective motor-neuron loss and paralysis.", "[56] Misfolded SOD1 inhibits VDAC1 conductance; VDAC1 reduction accelerates fatal paralysis in mutant-SOD1 mice." ], "what_would_cross_it": "A pre-onset, mechanistically engaged intervention or credible human natural instrument must separate mitochondria-first from protein-first and multi-hit models by incident disease and longitudinal function." }, { "subclaim_id": "SC6", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[58] A prospective randomized trial using prior-study-defined early-ALS eligibility shows less 24-week ALSFRS-R decline with edaravone.", "[60] EMPOWER finds no dexpramipexole benefit on prespecified combined function/survival or separate efficacy endpoints.", "[61] Olesoxime does not improve 18-month survival or sustained functional endpoints in riluzole-treated ALS.", "[62] An adaptive CoQ10 ALS trial finds insufficient promise to proceed, with null secondary outcomes and sensitivity-dependent futility analyses.", "[63] Powered sibling-matched SOD1 screening and primary TDP-43 neurons show no substantial dexpramipexole survival/progression benefit at clinically comparable exposure.", "[64] High-dose CoQ10 in early PD reaches prespecified futility without clinical UPDRS benefit.", "[65] Long-term NET-PD creatine randomization is stopped for futility on a composite clinical progression outcome.", "[66] STEADY-PD III isradipine shows no three-year clinical progression benefit or secondary benefit.", "[67] Original UDCA Methods define safety as primary; Results show midbrain MRS energetic changes and a small sensor-gait signal, with null UPDRS group contrasts.", "[68] NADPARK increases brain NAD variably and alters metabolic/inflammatory measures after 30 days.", "[69] NR-SAFE supports short-term high-dose tolerability and blood NAD elevation in 20 patients.", "[70] 2CARE high-dose CoQ10 in genetic HD is stopped for futility without functional-capacity or survival benefit." ], "what_would_cross_it": "A confirmatory trial must demonstrate relevant brain/cell engagement and sustained functional or survival benefit attributable to the proposed mitochondrial process." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Ndufs2 loss preserves retrogradely labelled neurons despite TH/dopamine downregulation.", "Parkin-null and POLG-mutator single lesions lack the aged double-mutant neuron loss.", "Young mutator mice resist increased MPTP vulnerability.", "CHCHD2 and CHCHD2/CHCHD10 deletion preserve DA neurons and OXPHOS.", "Healthy aged neurons maintain wild-type mtDNA by copy-number compensation.", "HD iPSC respiratory reserve is mostly retained despite glycolytic deficits.", "AD HeLa cybrids retain respiration unlike some NT2/SH-SY5Y platforms.", "CypD deletion preserves somata without preventing denervation or fatal paralysis in three SOD1 models.", "UDCA UPDRS contrasts are null and gait/MRS analyses are secondary and unpowered.", "Isradipine explicitly retains insufficient-target-engagement as a limitation." ], "note": "Prospective boundaries include genotype, lineage, age, lesion, compartment and treatment timing. Do not define susceptibility by post-treatment NAD response or complex-I deficiency discovered after disease. Forced severe lesions cannot stand for ageing, familial protein mutations cannot be renamed sporadic, and cell-body preservation cannot substitute for axon/function/survival trajectories. The registered HD wording is explicitly corrected in interpretation without altering the registered primary gate." }, "falsification_patterns_met": [ { "pattern": "Mitochondrial biomarker rescue can fail to alter disease trajectory", "evidence": "Engaged CypD deletion improves ATP/calcium buffering and motor-neuron survival but not denervation, progression or lifespan in three SOD1 models.", "downgrade_applied": false }, { "pattern": "Protein and other metabolic processes can lie upstream", "evidence": "HTT repression, alpha-synuclein import inhibition and SOD1 conductance effects coexist with largely retained HD respiratory reserve.", "downgrade_applied": false } ], "pitfalls_flagged": [ { "pitfall": "Dopamine-marker loss called neuronal death", "where": "Original Ndufs2 retrograde-label and compensation Results." }, { "pitfall": "Point-mutation mutator treated as sporadic deletion-specific cause", "where": "SC4 differs from combined POLG/Parkin lesions." }, { "pitfall": "Pre-onset transgene protection called late therapeutic reversal", "where": "Original NCLX induction at four weeks." }, { "pitfall": "All failed therapies declared adequately engaged", "where": "Isradipine limitation and UDCA/NADPARK biomarker specificity." }, { "pitfall": "Inherited HD called sporadic mitochondrial-first disease", "where": "Registered wording is scientifically ill-posed and explicitly qualified." }, { "pitfall": "Provider substituted reviews or irrelevant knockout cited as original checks", "where": "Consensus missing four focal originals and irrelevant alpha9 compensation example." }, { "pitfall": "Respiration equated to total ATP metabolism", "where": "HD glycolysis, PGK1 and Ndufs2 glycolytic compensation." } ], "causal_tally_audit": { "tally_claimed_by_document": 37, "tally_after_audit": 37, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "Shared cohorts, experimental platforms, transgenic lineages and repeated outcomes do not constitute fully independent causal lines." ] }, "steelman": { "case_one_rung_higher": "The best case for Δ or higher for mitochondrial-first causality combines endogenous lesion sufficiency, mtDNA transfer and early NCLX changes before model plaques, plus metabolic human engagement. These establish more than passive association. They do not yet isolate the age-related initiating process across sporadic diseases, and HD begins with HTT. The model sufficiency set receives Ζ separately rather than being suppressed.", "case_one_rung_lower": "A Β-only account misses adult mediator subtraction, Nissl-confirmed progressive loss and respiratory genetic editing. The nominal inference is supported mechanistically even though its ordinary human etiological apex is unresolved.", "which_rejected": "Γ is appropriate for SC5 while Ζ/Ε preserve narrower causal successes. Neither all-mitochondria-first nor mitochondria-as-passive-consequence fits the full evidence. Null drug regimens constrain implementation; only verified mechanistic nulls constrain the precise driver.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: In baseline genotype-, reserve- and protein-state-defined aged cohorts or validated natural-instrument cohorts, selectively preserve the implicated mitochondrial process before protein pathology, with matched protein-directed perturbation and mechanistic rescue. Follow incident disease, cell fate and function. Predefine disease-specific boundaries rather than pooling genetic HD with sporadic syndromes." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "Multiple independent causal lines across mouse, rat, fly and human cellular systems, but substantial heterogeneity in preparation and controls and unreconciled discrepancies (complex-I subtype variation, cybrid nuclear background, CypD survival effects) limit reproducibility. Access depth is not a determinant. Confidence reflects evidence density and reproducibility, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "Scope-matched SC5 gives Γ. Endogenous mitochondrial lesions demonstrate convergent model causality (SC2 Ζ), and HD biogenesis has contextual contribution (SC3 Ε). Neither set identifies age-related respiratory failure as the spontaneous upstream cause across disease classes. The registered phrase sporadic Huntington disease is scientifically ill-posed: the examined HTT disease is genetically initiated, and is retained as an explicit counterexample rather than silently recast." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": 5, "derivation": "In the broad disease class, mitochondrial processes can amplify injury and set reserve; removal/rescue changes selected model trajectories. Severe mitochondrial lesions can initiate disease in their own scope, and metabolic reserve can be permissive. Neither observation establishes a common rate-limiting human initiator; the class-level role does not erase narrow sufficiency.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "2025 complex-IV editing and 2026 neuronal MCU loss/mitochondrial transfer test causal or rescue boundaries. The examined UDCA and NR phase-I/II reports do not establish current recruitment or a pending decisive clinical result.", "justification": "2025 complex-IV editing and 2026 neuronal MCU loss/mitochondrial transfer test causal or rescue boundaries. The examined UDCA and NR phase-I/II reports do not establish current recruitment or a pending decisive clinical result." }, "stability": { "value": "Stable", "trigger": "No verified named pending human result is asserted likely to change the nominal primacy score imminently. A pre-onset subtype-specific engaged clinical benefit would change SC5/SC6.", "justification": "No verified named pending human result is asserted likely to change the nominal primacy score imminently. A pre-onset subtype-specific engaged clinical benefit would change SC5/SC6." }, "divergence": { "implied_level": null, "implied_level_basis": "No single field-implied level is defensible from conflicting framings.", "assessed_level": "Γ", "gap_in_rungs": null, "value": "Contested", "justification": "No manufactured field consensus or arithmetic gap." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "Ranking categorical verdict visible; no prior letter used as a target", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": false, "new_level": "Γ", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "In baseline genotype-, reserve- and protein-state-defined aged cohorts or validated natural-instrument cohorts, selectively preserve the implicated mitochondrial process before protein pathology, with matched protein-directed perturbation and mechanistic rescue. Follow incident disease, cell fate and function. Predefine disease-specific boundaries rather than pooling genetic HD with sporadic syndromes.", "readout": "Incident adjudicated disease, chronological protein/mitochondrial change, labelled neuronal and axonal survival, motor/cognitive function and lifespan", "critical_control": "Cell-specific engagement, general viability, genotype, baseline reserve, protein burden, developmental compensation, treatment timing and symptomatic medication; selective lesion reinstatement", "supporting_result": "Mitochondrial preservation prevents protein pathology and disease in the predicted baseline strata, with matched rescue and independent natural or clinical confirmation", "falsifying_result": "Adequate early mitochondrial correction leaves onset unchanged, protein-directed perturbation prevents the mitochondrial lesion, or reserve thresholds fail to predict vulnerability" } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Separate actual neuron/axon survival from neurotransmitter phenotype and somatic compensation.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Identify deletion-specific causal effects and wild-type-copy compensation before sporadic PD onset.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Resolve cell type and bioenergetic subtype prospectively rather than selecting deficient brains after death.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "Compare glycolytic reserve, respiration and ATP-demand failure instead of equating them.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "Reconcile CypD lifespan discrepancies across sex, background and SOD1 alleles using blinded matched designs.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 6", "statement": "Test NCLX/MCU and quality-control rescue after established pathology rather than only early prevention.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 7", "statement": "Pair human bioenergetic engagement with selective sustained clinical benefit and medication-aware endpoints.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 8", "statement": "Define mitochondrial mediators separately in inherited HTT disease and sporadic AD/PD/ALS.", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-07", "reviewer": "Codex", "evidence_base_note": "70 primary reports; literature cutoff 2026-10-07; source examination UTC date 2026-10-07; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Entrez; attempted Europe PMC XML and successful public NCBI PMC direct HTTPS access are separately logged. Signed-in Consensus browser discovery and targeted indexed full-text checks are reconciled with original sections; failed matches and source substitutions remain explicit. Zero Consensus API calls. SciSpace discovery was also used; matched primary leads were resolved to original records before counting. See scispace-leads.json.", "skill_version": "5.3", "validator_run": "exact archived v5.3 validator 2.3; see validator.txt", "validator_warnings_addressed": "Phenomenon entry was restated as the preregistered causal claim. No real phenomenon is labelled refuted; warning is explicitly justified.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Ranking categorical verdict and index guidance were visible. No completed blinded calibration claimed." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "Human PINK1 genetics, occupational exposure contrasts and randomized therapeutic endpoints were considered. None isolates ordinary age-related mitochondrial failure as the mediator of sporadic onset. A randomized preventive test is not required in principle: convergent natural instruments and mechanistically specific clinical trajectories could cross upper levels. Current phase-I biomarker engagement, postdiagnosis null drugs and familial instruments cover different weaknesses but do not jointly close the nominal causal chain." }, { "kind": "natural_experiment", "available": true, "why_not_sufficient": "Human PINK1 genetics, occupational exposure contrasts and randomized therapeutic endpoints were considered. None isolates ordinary age-related mitochondrial failure as the mediator of sporadic onset. A randomized preventive test is not required in principle: convergent natural instruments and mechanistically specific clinical trajectories could cross upper levels. Current phase-I biomarker engagement, postdiagnosis null drugs and familial instruments cover different weaknesses but do not jointly close the nominal causal chain." }, { "kind": "dose_response_across_populations", "available": true, "why_not_sufficient": "Human PINK1 genetics, occupational exposure contrasts and randomized therapeutic endpoints were considered. None isolates ordinary age-related mitochondrial failure as the mediator of sporadic onset. A randomized preventive test is not required in principle: convergent natural instruments and mechanistically specific clinical trajectories could cross upper levels. Current phase-I biomarker engagement, postdiagnosis null drugs and familial instruments cover different weaknesses but do not jointly close the nominal causal chain." }, { "kind": "withdrawal_rechallenge", "available": false, "why_not_sufficient": "Human PINK1 genetics, occupational exposure contrasts and randomized therapeutic endpoints were considered. None isolates ordinary age-related mitochondrial failure as the mediator of sporadic onset. A randomized preventive test is not required in principle: convergent natural instruments and mechanistically specific clinical trajectories could cross upper levels. Current phase-I biomarker engagement, postdiagnosis null drugs and familial instruments cover different weaknesses but do not jointly close the nominal causal chain." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": true, "why_not_sufficient": "Human PINK1 genetics, occupational exposure contrasts and randomized therapeutic endpoints were considered. None isolates ordinary age-related mitochondrial failure as the mediator of sporadic onset. A randomized preventive test is not required in principle: convergent natural instruments and mechanistically specific clinical trajectories could cross upper levels. Current phase-I biomarker engagement, postdiagnosis null drugs and familial instruments cover different weaknesses but do not jointly close the nominal causal chain." } ], "convergence_present": true, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 70, "claims_total": 77, "claims_verified": 77, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 70, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "DA-lineage Tfam deletion impairs respiratory-chain expression and produces adult progressive parkinsonism and neuron loss in MitoPark mice. Forced broad mitochondrial transcription loss is not normal aging or proof of sporadic initiation; inclusions are not equivalent to Lewy proteinopathy; original body unavailable here.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C2", "text": "Ndufs2 conditional deletion causes progressive dopamine dysfunction with glycolytic compensation; original Results retain retrogradely labelled cell bodies at P60 despite marker downregulation. This developmental lineage deletion establishes functional parkinsonism, not early neuron death; retained somatic integrity limits marker-based degeneration claims; linked erratum details unexamined.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Loss of MCI induces metabolic reprogramming:paragraph0, 0:Loss of MCI induces metabolic reprogramming:paragraph1, 0:Loss of MCI induces metabolic reprogramming:paragraph2, 1:Early axonal dysfunction after Ndufs2 deletion:paragraph0, 2:Somatodendritic shift after Ndufs2 deletion:paragraph0, 2:Somatodendritic shift after Ndufs2 deletion:paragraph1, 4:Nigral determinants of motor disability:paragraph2, 4:Nigral determinants of motor disability:paragraph3, 4:Nigral determinants of motor disability:paragraph4. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C3", "text": "Single aged substantia-nigra neurons contain clonally expanded mtDNA deletions associated with respiratory deficiency. Postmortem functional association lacks deletion-selective manipulation, pre-onset order or tracked neuronal fate.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C4", "text": "High mtDNA deletion burdens accompany respiratory-chain deficiency in aged and PD substantia nigra. Aged controls also carry high burdens; lesion presence does not establish differential death or etiological primacy.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C5", "text": "Original Results confirm aged Parkin-null/POLG-mutator double mutants lose TH-positive and Nissl-counted neurons and show levodopa-responsive motor impairment; neither lesion alone does so. Constitutive combined genetic stress models conditional vulnerability, not sporadic deletion primacy; Parkin loss does not increase total mutation burden and levodopa is symptomatic rescue.", "carries_number": false, "load_bearing_for": [ "SC2", "SC4", "SC5" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph5, 1:RESULTS:paragraph10, 1:RESULTS:paragraph11, 1:RESULTS:paragraph13. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C6", "text": "Pink1-deficient flies show mitochondrial and muscular pathology plus dopaminergic degeneration; Parkin expression rescues mitochondrial and motor defects. Constitutive fly loss and transgenic rescue do not establish spontaneous human disease or distinguish every Parkin function from bioenergetics.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C7", "text": "Independent Pink1 fly experiments link mitochondrial dysfunction and muscle degeneration to a Parkin-responsive pathway. The abstract emphasizes muscle and fertility; it cannot be credited as a distinct mammalian neuronal-survival experiment or evidence of sporadic primacy.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C8", "text": "Aged controls compensate deletion burden with increased mtDNA copy number; this maintenance of wild-type mtDNA is deficient in PD neurons. Cross-sectional surviving cells do not resolve whether failed compensation precedes disease or follows proteinopathy.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C9", "text": "Young POLG-mutator mice do not show increased MPTP vulnerability by dopamine-neuron counts and striatal dopamine measurements. This is an age- and insult-specific negative result, not exclusion of late-life combined Parkin/mutation pathology.", "carries_number": false, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C10", "text": "Original adult conditional Parkin-loss Results show PARIS/PGC-1alpha changes before progressive TH and Nissl neuron loss; PARIS knockdown attenuates that loss. Germline Parkin deletion compensates; PGC-1alpha survival rescue is in PARIS overexpression rather than a selective human-ageing lesion; human tissue remains associative.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph8, 1:RESULTS:paragraph9, 1:RESULTS:paragraph18, 1:RESULTS:paragraph19, 1:RESULTS:paragraph20, 1:RESULTS:paragraph22. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C11", "text": "Adult Parkin knockout reduces mitochondrial mass; PARIS knockdown prevents mass changes and PARIS overexpression disrupts PGC-1alpha-dependent respiration. The same PARIS/Parkin platform is a mechanistic extension rather than an independent sporadic initiation line; organelle markers do not independently prove cell death.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C12", "text": "PARIS CRISPR knockdown restores biogenesis and mitochondrial function in PARKIN-deficient human dopamine neurons while mitophagy defects persist. In-vitro genetic cells separate biogenesis from mitophagy but do not demonstrate organismal progression or sporadic upstream order.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C13", "text": "Fly PINK1/Parkin insufficiency produces PARIS-linked biogenesis deficits and TH-positive neuronal/motor changes reversed by pathway overexpression. TH immunostaining alone may conflate identity and survival; constitutive and overexpression methods constrain inference; related PARIS biology shares failure modes.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C14", "text": "Farnesol limits PARIS promoter repression and protects neuronal and behavioral phenotypes across adult Parkin-loss and artificial alpha-synuclein/PARIS settings. Pharmacological specificity and constructed models restrict generalization; multiple models in one programme are not independent human etiological confirmation.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C15", "text": "DA-specific, brain-wide and whole-body CHCHD2 loss preserve DA neurons and OXPHOS; double CHCHD2/CHCHD10 loss also preserves midbrain neurons. Absence of loss-of-function pathology does not refute a pathogenic CHCHD2 gain-of-function mutation; gene identity alone cannot diagnose respiratory failure.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C16", "text": "Endogenous CHCHD2 T61I knock-in causes age-related motor deficits, DA loss, mitochondrial abnormalities and alpha-synuclein accumulation. A familial pathogenic mutation with inferred IDE effects is not proof that ordinary bioenergetic decline initiates sporadic PD; direction requires temporal separation.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C17", "text": "Modified alpha-synuclein inhibits TOM20-mediated import; endogenous alpha-synuclein lowering preserves import in a PD model and human tissue shows the interaction. Protein-driven mitochondrial disruption provides a reverse-direction route; import or in-vitro TOM20 rescue alone is not human survival or initiation proof.", "carries_number": true, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C18", "text": "Injected alpha-synuclein PFFs produce neuronal loss and mitochondrial ATP/redox abnormalities in vulnerable dopamine and cholinergic populations. Forced seeding places protein pathology upstream experimentally; it cannot establish natural onset or turn a mitochondrial proximal mediator into the initiating cause.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C19", "text": "Idiopathic PD stratifies by widespread neuronal complex-I deficiency, with distinct molecular and clinical profiles and deletion burden. Postmortem subtype classification is not pre-onset causal identification; many cases lack extra-nigral impairment and outcome-defined strata cannot rescue a universal claim.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4", "SC5" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C20", "text": "Modest PGK1 augmentation improves neuronal ATP kinetics and synaptic function; viral expression protects dopamine axons from metabolic lesions. Glycolytic support and axonal function are broader than mitochondrial respiration; induced lesions and marker endpoints do not prove neuronal survival in sporadic PD.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C21", "text": "USP30 genetic loss and a brain-penetrant inhibitor attenuate alpha-synuclein-induced DA loss and motor deficits while increasing mitophagy. A protein-triggered model supports a modifiable downstream quality-control contribution; it does not establish mitochondrial-first onset in humans.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C22", "text": "Encapsulated mitochondrial transfer rescues bioenergetics in patient cells and phenotypes in mitochondrial-disease mice, with neuronal/motor rescue in a PD model. Organelle delivery is pleiotropic and induced-model specific; no human PD trajectory is established; linked correction details are unexamined.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C23", "text": "Gram-negative infection in Pink1-null mice elicits mitochondrial-antigen CD8 responses, striatal varicosity loss and levodopa-responsive motor impairment. The demonstrated phenotype is immune-context-dependent axonal dysfunction, not established nigral cell death or unconditional respiratory-loss sufficiency.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C24", "text": "A nested agricultural case-control study links rotenone/paraquat exposure groups to diagnosed PD. Recall, co-exposures and non-mitochondrial toxic actions prevent a selective instrument or proof that age-related respiration failure mediates onset.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C25", "text": "BCKDK loss destabilizes complex I and promotes alpha-synuclein pathology; restoring BCKDK rescues respiration and partly restores patient-derived cell markers. Stress-conditioned cellular rescue and postmortem associations do not establish spontaneous in-vivo neuronal loss or mitochondrial primacy.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C26", "text": "Two homozygous PINK1 Q456X relatives develop early PD with loss of kinase/Parkin-substrate function; heterozygous carriers remain unaffected. Familial gene causality and peripheral fibroblast assays do not isolate bioenergetics from immune/quality-control actions or explain sporadic late-life disease.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C27", "text": "Whole-mitochondrial sequencing of disease/control brains finds no major disease association for rare inherited or heteroplasmic point variants, with some copy-number differences. Bulk tissue may miss single-cell deletion lesions; a point-mutation null cannot exclude deletion/compartment effects; linked erratum details unexamined.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4", "SC5" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C28", "text": "PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice; PGC-1alpha expression rescues induced neuronal toxicity and protects transgenic striatum. Mutant huntingtin represses PGC-1alpha upstream; global biogenesis loss and overexpression rescue support contribution within genetic HD, not sporadic mitochondrial initiation.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C29", "text": "HD mice show thermoregulatory, mitochondrial and PGC-1alpha target abnormalities; exogenous PGC-1alpha protects striatal cells from a mitochondrial toxin. Brown-fat and toxin phenotypes do not independently prove endogenous striatal necessity or an etiological apex; huntingtin is the defined initiating mutation.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C30", "text": "Bezafibrate restores biogenesis/antioxidant signatures and ameliorates motor and striatal pathology in full-length BACHD mice. A pan-PPAR agonist is pleiotropic; benefits under mutant HTT do not identify biogenesis alone or reverse genetic upstream order.", "carries_number": false, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C31", "text": "Original Results show reduced ATP and spare glycolytic capacity with largely retained respiratory reserve; late glycolytic metabolites improve ATP and mutant-HTT neuron viability. One long-repeat line has reduced maximal respiration; rescue in transfected mouse neurons differs from human-cell ATP rescue; small donor panels and artificial cultures limit generalization.", "carries_number": false, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph9, 1:Results:paragraph11, 1:Results:paragraph14. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C32", "text": "The common mtDNA deletion is lower in two HD regions and unchanged in caudate, with similar respiratory-polypeptide staining. Bulk gliosis can replace deletion-rich neurons and obscure vulnerability; this does not exclude every mitochondrial lesion.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C33", "text": "HD platelet-mtDNA cybrids resemble control cybrids in respiration, oxidative stress and calcium assays. The model excludes nuclear mutant HTT and tissue-specific effects; it constrains mitochondrial inheritance claims rather than all HD metabolic mechanisms.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C34", "text": "Isolated synaptic/non-synaptic mitochondria and R6/2 striatal cultures show retained respiration, ATP and calcium handling. Age, preparation and fragment-model conditions bound this negative result; isolated organelles can omit intact-neuron interactions.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C35", "text": "Affected HD-model brain tissue has increased glycolytic flux and ATP with altered enzyme activity and a fitted metabolic model. Whole-tissue averages and partially predictive kinetic modelling do not establish neuronal ATP sufficiency or validate the proposed enzyme-channeling explanation.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C36", "text": "Protease/alkali localization and respiratory assays place mutant HTT outside the mitochondrial outer membrane with no TIM23 import deficit in the examined preparations. This challenges a specific import route, not every HTT-mitochondrial interaction or stage of HD; postmortem and isolation constraints persist.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C37", "text": "Brain-specific PPARGC1A isoforms and regional haplotypes associate with HD onset age and show neuronal promoter activity. Association of a broad regulatory locus is not a selective causal instrument for mitochondrial biogenesis or proof of primary initiation.", "carries_number": true, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C38", "text": "Cyclophilin-D deletion protects mitochondrial calcium handling and neuronal stress responses while improving cognition and synaptic function in an amyloid model. A-beta acts upstream of pore stress; lifelong knockout and model cognition do not establish sporadic onset or clinical disease modification.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C39", "text": "Ebselen/CypD blockade improves bioenergetics in sporadic AD cybrids and cognition, synaptic/inflammatory phenotypes in AD mice. Ebselen has additional redox actions and induced-model benefits; no clinical trajectory or unique upstream cause is shown.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C40", "text": "Original NCLX deletion accelerates 3xTg-AD pathology/cognitive decline; regulated early postnatal NCLX expression preserves cognition and calcium handling with activity controls. The rescue starts at four weeks, before disease, rather than reversing established dementia; 3xTg mutations and a roughly twofold transgene are not sporadic etiological proof.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph3, 1:Results:paragraph7, 1:Results:paragraph9, 1:Results:paragraph14. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C41", "text": "Neuronal NCLX loss alone induces age-related memory deficits, mild protein pathology and cell-death indicators without pre-existing amyloid/tau mutations. A severe engineered efflux lesion and indications of death are not normal aging or proof of human universal initiation.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C42", "text": "Conditional neuronal MCU loss reduces pathology and cognitive dysfunction in 3xTg-AD with autophagic and mitochondrial preservation. Protection in a familial transgenic setting supports calcium dependence; the corresponding preprint is the same study, not independent replication or human disease modification.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C43", "text": "AD platelet-mtDNA cybrids display reduced COX activity and increased ROS/scavenging activity in a standardized nuclear background. Transfer into mtDNA-depleted tumor cells is artificial; the abstract infers mutations without identifying a causal variant or establishing prediagnostic neuronal onset.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C44", "text": "AD cybrids show mitochondrial depolarization, caspase/A-beta changes and pharmacological modulation of A-beta secretion. Selected cell lines and broad antioxidants/caspase inhibitors cannot establish primary in-vivo disease onset or unique mtDNA causality.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C45", "text": "MCI platelet-mtDNA cybrids show COX and oxidative-stress deficits and AD cybrids contain increased mitochondrial A-beta. MCI is not pathology-free or necessarily pre-amyloid; cross-sectional transfer cannot prove mitochondrial change precedes proteinopathy in donors.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C46", "text": "AD platelet and brain-synaptosome mtDNA restores respiration similarly to age-matched controls in HeLa cybrids. Different nuclear background and cell selection could alter sensitivity; the null contradicts universal transferable respiratory failure without excluding brain-specific interactions.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C47", "text": "Acute/chronic mtDNA depletion and AD cybrid transfer increase tau oligomers in SH-SY5Y cells. Ethidium-bromide stress, rho-zero adaptation and common transformed-cell platforms share failure modes; no human onset or neuronal fate is demonstrated.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C48", "text": "MCI/AD donor-mtDNA cybrids show altered tau phosphorylation and proteomes, correlating with donor plasma, cognition and morphology. Constructed cells and cross-sectional donor correlations do not track causal onset or selective mitochondrial disease prevention.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C49", "text": "Induced familial PS1 mutations disturb mitochondrial/MAM physiology; ATL2 lowering corrects abnormal contacts in cells. Genetically determined protein changes are upstream in this design; morphology rescue and familial cell lines do not establish mitochondrial primacy in sporadic AD.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C50", "text": "Isogenic APOE4 astrocytes show lysosomal cholesterol retention and respiratory defects rescued by cholesterol depletion. The cellular pathway is genotype/lysosome-led; no human neuronal trajectory or exclusive respiration-mediated risk is established.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C51", "text": "Trem1 loss preserves metabolic, inflammatory and memory phenotypes in ageing and amyloid mice; postmortem expression tracks AD severity. A myeloid inflammatory intervention is not selective neuronal mitochondrial restoration, and amyloid-linked effects do not identify the initial sporadic event.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C52", "text": "CypD deletion improves calcium buffering, ATP, morphology and motor-neuron survival across three SOD1 mutants without improving denervation, progression or lifespan. This is an engaged genetic dissociation between soma preservation and fatal paralysis; it bounds the pore mechanism, not every mitochondrial process or human sporadic ALS.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C53", "text": "CypD reduction delays onset and extends lifespan in G93A-SOD1 mice with sex- and expression-dependent patterns. Later multi-mutant experiments fail to reproduce disease-trajectory benefit despite engagement; model/background discrepancies remain unresolved.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C54", "text": "TDP-43 releases mitochondrial DNA and cGAS/STING suppression prevents downstream inflammatory signalling in cells and mutant mice. TDP-43 is upstream experimentally; cytokine suppression and patient cGAMP do not establish mitochondrial-first disease or restored human function.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C55", "text": "Targeted mitochondrial complex-IV mutations in rat neurons induce TDP-43 redistribution, selective motor-neuron loss and paralysis. Engineered sufficiency does not identify spontaneous sALS initiation; correction details unexamined and reported human-deficiency prevalence is not independently audited here.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C56", "text": "Misfolded SOD1 inhibits VDAC1 conductance; VDAC1 reduction accelerates fatal paralysis in mutant-SOD1 mice. This places protein toxicity before mitochondrial impairment and tests a familial interaction, not a universal mitochondrial initiator.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C57", "text": "ALS tissue/models show reduced Miro1 and glutamate challenge lowers Miro1 in motor neurons. Expression and excitotoxic challenge support a downstream transport route; selective transport rescue with survival is absent from the examined abstract.", "carries_number": true, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 57 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C58", "text": "A prospective randomized trial using prior-study-defined early-ALS eligibility shows less 24-week ALSFRS-R decline with edaravone. This establishes a restricted antioxidant clinical effect, not specific mitochondrial restoration or upstream cause; broad efficacy cannot be inferred from the selected cohort.", "carries_number": true, "load_bearing_for": [ "SC6" ], "source_ns": [ 58 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C59", "text": "A propensity-matched German long-term cohort finds no ALS progression, ventilation or survival advantage with edaravone, including eligibility-defined strata. Treatment selection, residual confounding and exposure/completer selection prevent equivalence to randomized rejection; linked correction details unexamined.", "carries_number": false, "load_bearing_for": [ "SC6" ], "source_ns": [ 59 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C60", "text": "EMPOWER finds no dexpramipexole benefit on prespecified combined function/survival or separate efficacy endpoints. A drug-regimen null with uncertain cellular target engagement cannot falsify every mitochondrial driver; an author-name correction is retained.", "carries_number": false, "load_bearing_for": [ "SC6" ], "source_ns": [ 60 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C61", "text": "Olesoxime does not improve 18-month survival or sustained functional endpoints in riluzole-treated ALS. Blood levels do not establish mitochondrial occupancy in target motor neurons; one transient secondary signal is not sustained disease modification.", "carries_number": true, "load_bearing_for": [ "SC6" ], "source_ns": [ 61 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C62", "text": "An adaptive CoQ10 ALS trial finds insufficient promise to proceed, with null secondary outcomes and sensitivity-dependent futility analyses. A futility design is not a conventional superiority trial and does not establish adequate CNS mitochondrial engagement or mechanism absence.", "carries_number": true, "load_bearing_for": [ "SC6" ], "source_ns": [ 62 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C63", "text": "Powered sibling-matched SOD1 screening and primary TDP-43 neurons show no substantial dexpramipexole survival/progression benefit at clinically comparable exposure. Negative compound performance constrains translational rationale rather than every mitochondrial mechanism; a marginal single cellular indicator is retained.", "carries_number": true, "load_bearing_for": [ "SC2", "SC6" ], "source_ns": [ 63 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C64", "text": "High-dose CoQ10 in early PD reaches prespecified futility without clinical UPDRS benefit. This treatment failure does not establish adequate neuronal engagement, timing or complete disproof of bioenergetic contribution.", "carries_number": true, "load_bearing_for": [ "SC6" ], "source_ns": [ 64 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C65", "text": "Long-term NET-PD creatine randomization is stopped for futility on a composite clinical progression outcome. Energy buffering is broad and clinical treatment begins after diagnosis; neuronal mitochondrial correction is not demonstrated by this outcome.", "carries_number": false, "load_bearing_for": [ "SC6" ], "source_ns": [ 65 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C66", "text": "STEADY-PD III isradipine shows no three-year clinical progression benefit or secondary benefit. The original abstract explicitly allows insufficient neuroprotective calcium-channel engagement; a universal engaged-mechanism null would overstate it.", "carries_number": false, "load_bearing_for": [ "SC6" ], "source_ns": [ 66 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C67", "text": "Original UDCA Methods define safety as primary; Results show midbrain MRS energetic changes and a small sensor-gait signal, with null UPDRS group contrasts. Thirty-one were randomized; MRS/gait subsets are smaller, secondary analyses unpowered and unadjusted for multiplicity; no established disease-modifying trajectory or cell-specific adequate engagement.", "carries_number": false, "load_bearing_for": [ "SC6" ], "source_ns": [ 67 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph8, 2:Results:paragraph0, 2:Results:paragraph5, 2:Results:paragraph6, 2:Results:paragraph7, 2:Results:paragraph8. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C68", "text": "NADPARK increases brain NAD variably and alters metabolic/inflammatory measures after 30 days. Phase-I biomarker engagement and responder-associated clinical change do not establish progression; response-defined subsets cannot prospectively define scope.", "carries_number": true, "load_bearing_for": [ "SC6" ], "source_ns": [ 68 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C69", "text": "NR-SAFE supports short-term high-dose tolerability and blood NAD elevation in 20 patients. Clinical change covaries with time since levodopa; four weeks and blood metabolites cannot establish mitochondrial disease modification.", "carries_number": true, "load_bearing_for": [ "SC6" ], "source_ns": [ 69 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "C70", "text": "2CARE high-dose CoQ10 in genetic HD is stopped for futility without functional-capacity or survival benefit. The initiating HTT mutation is distinct from mitochondrial support; no adequate neuronal biochemical engagement is established by the null clinical outcome.", "carries_number": true, "load_bearing_for": [ "SC6" ], "source_ns": [ 70 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-07", "note": "" }, { "id": "CSC1", "text": "Respiratory, mtDNA and metabolic abnormalities are reproducibly present, but variation by cell, disease and preparation is substantial. A descriptive tissue association is Β; it neither negates nor supplies causal perturbation.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 3, 4, 8, 17, 19, 24, 27, 32, 33, 35, 45, 48, 57 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-07", "note": "" }, { "id": "CSC2", "text": "Tfam disruption, conditional adult Parkin/PARIS loss with Nissl-confirmed degeneration, combined POLG/Parkin stress and rat complex-IV editing provide distinct endogenous routes to disease-relevant injury. Model-level mitochondrial sufficiency reaches Ζ as a set. Ndufs2 primarily produces dysfunction with somatic survival and is not falsely counted as death. Contradictory pore effects and lesion severity block a uniform Η trajectory claim; sporadic human primacy is a separate subclaim.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 2, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 21, 22, 23, 25, 26, 38, 39, 40, 41, 42, 43, 44, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 63 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-07", "note": "" }, { "id": "CSC3", "text": "Endogenous PGC-1alpha deletion worsens striatal degeneration in HD knock-in mice and matched gain-of-function/PPAR approaches preserve phenotypes. This is genuine context-dependent biogenesis contribution (Ε), despite pleiotropy. Mutant HTT is upstream; donor-cell glycolytic and isolated-respiration counterexamples limit generalization and exclusive bioenergetic explanation.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 28, 29, 30, 31, 34, 36, 37 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-07", "note": "" }, { "id": "CSC4", "text": "Single-cell deletion burden has a plausible respiratory effect and healthy aged cells compensate, but no deletion-selective pre-onset manipulation tracks sporadic PD neuron fate. POLG/Parkin point-mutation interaction is not the same lesion. Combined mechanistic support gives Γ, not demonstrated deletion primacy.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 3, 4, 5, 8, 9, 19, 27 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-07", "note": "" }, { "id": "CSC5", "text": "Mitochondrial-first engineered models and transferred cybrids coexist with protein-first import, permeability and immune pathways. No human temporal/counterfactual set establishes an etiological apex across sporadic AD, PD and ALS. Genetic HD starts with HTT, and mitochondria can modify its consequences. Γ applies to the broad initiating inference, not to the assembled narrow lesion causality.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 1, 2, 5, 6, 7, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-07", "note": "" }, { "id": "CSC6", "text": "Large PD/ALS/HD drug trials are often null, but adequate neuronal engagement is not universally demonstrated. UDCA and NADPARK demonstrate human bioenergetic/metabolic changes without confirmed disease modification. Restricted edaravone functional benefit is not a selective mitochondrial restoration experiment. Mechanistically attributable clinical trajectory change remains Γ.", "carries_number": false, "load_bearing_for": [ "SC6" ], "source_ns": [ 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-07", "note": "" }, { "id": "CH", "text": "Mitochondrial impairment can cause or amplify neuronal injury, but it is not established as the common initiating apex of sporadic neurodegeneration.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 5, 2, 31, 52, 67 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-07", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Ekstrand MI, Terzioglu M, Galter D et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America. 2007.", "tier": "A", "kind": "primary", "pmid": "17227870", "doi": "10.1073/pnas.0605208103", "url": "https://pubmed.ncbi.nlm.nih.gov/17227870/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID17227870", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC2", "CSC5" ] }, { "n": 2, "citation": "González-Rodríguez P, Zampese E, Stout KA et al. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature. 2021.", "tier": "A", "kind": "primary", "pmid": "34732887", "doi": "10.1038/s41586-021-04059-0", "url": "https://pubmed.ncbi.nlm.nih.gov/34732887/", "status_flags": [ "ErratumIn: PMID35149834" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID34732887", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Loss of MCI induces metabolic reprogramming:paragraph0, 0:Loss of MCI induces metabolic reprogramming:paragraph1, 0:Loss of MCI induces metabolic reprogramming:paragraph2, 1:Early axonal dysfunction after Ndufs2 deletion:paragraph0, 2:Somatodendritic shift after Ndufs2 deletion:paragraph0, 2:Somatodendritic shift after Ndufs2 deletion:paragraph1, 4:Nigral determinants of motor disability:paragraph2, 4:Nigral determinants of motor disability:paragraph3, 4:Nigral determinants of motor disability:paragraph4. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC2", "CSC5", "CH" ] }, { "n": 3, "citation": "Kraytsberg Y, Kudryavtseva E, McKee AC et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nature genetics. 2006.", "tier": "A", "kind": "primary", "pmid": "16604072", "doi": "10.1038/ng1778", "url": "https://pubmed.ncbi.nlm.nih.gov/16604072/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID16604072", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC1", "CSC4" ] }, { "n": 4, "citation": "Bender A, Krishnan KJ, Morris CM et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nature genetics. 2006.", "tier": "A", "kind": "primary", "pmid": "16604074", "doi": "10.1038/ng1769", "url": "https://pubmed.ncbi.nlm.nih.gov/16604074/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID16604074", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC1", "CSC4" ] }, { "n": 5, "citation": "Pickrell AM, Huang CH, Kennedy SR et al. Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress. Neuron. 2015.", "tier": "A", "kind": "primary", "pmid": "26182419", "doi": "10.1016/j.neuron.2015.06.034", "url": "https://pubmed.ncbi.nlm.nih.gov/26182419/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID26182419", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph1, 1:RESULTS:paragraph2, 1:RESULTS:paragraph5, 1:RESULTS:paragraph10, 1:RESULTS:paragraph11, 1:RESULTS:paragraph13. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC2", "CSC4", "CSC5", "CH" ] }, { "n": 6, "citation": "Park J, Lee SB, Lee S et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006.", "tier": "A", "kind": "primary", "pmid": "16672980", "doi": "10.1038/nature04788", "url": "https://pubmed.ncbi.nlm.nih.gov/16672980/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID16672980", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC2", "CSC5" ] }, { "n": 7, "citation": "Clark IE, Dodson MW, Jiang C et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006.", "tier": "A", "kind": "primary", "pmid": "16672981", "doi": "10.1038/nature04779", "url": "https://pubmed.ncbi.nlm.nih.gov/16672981/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID16672981", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC2", "CSC5" ] }, { "n": 8, "citation": "Dölle C, Flønes I, Nido GS et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nature communications. 2016.", "tier": "A", "kind": "primary", "pmid": "27874000", "doi": "10.1038/ncomms13548", "url": "https://pubmed.ncbi.nlm.nih.gov/27874000/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID27874000", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC1", "CSC4" ] }, { "n": 9, "citation": "Dai Y, Clark J, Zheng K et al. Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice. Neurotoxicology and teratology. 2014.", "tier": "A", "kind": "primary", "pmid": "25450660", "doi": "10.1016/j.ntt.2014.10.004", "url": "https://pubmed.ncbi.nlm.nih.gov/25450660/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID25450660", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC2", "CSC4" ] }, { "n": 10, "citation": "Shin JH, Ko HS, Kang H et al. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell. 2011.", "tier": "A", "kind": "primary", "pmid": "21376232", "doi": "10.1016/j.cell.2011.02.010", "url": "https://pubmed.ncbi.nlm.nih.gov/21376232/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "Parkin-PARIS-platform", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph8, 1:RESULTS:paragraph9, 1:RESULTS:paragraph18, 1:RESULTS:paragraph19, 1:RESULTS:paragraph20, 1:RESULTS:paragraph22. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC2", "CSC5" ] }, { "n": 11, "citation": "Stevens DA, Lee Y, Kang HC et al. Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proceedings of the National Academy of Sciences of the United States of America. 2015.", "tier": "A", "kind": "primary", "pmid": "26324925", "doi": "10.1073/pnas.1500624112", "url": "https://pubmed.ncbi.nlm.nih.gov/26324925/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "Parkin-PARIS-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC2", "CSC5" ] }, { "n": 12, "citation": "Kumar M, Acevedo-Cintrón J, Jhaldiyal A et al. Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. Stem cell reports. 2020.", "tier": "A", "kind": "primary", "pmid": "32795422", "doi": "10.1016/j.stemcr.2020.07.013", "url": "https://pubmed.ncbi.nlm.nih.gov/32795422/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "Parkin-PARIS-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC2", "CSC5" ] }, { "n": 13, "citation": "Pirooznia SK, Yuan C, Khan MR et al. PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. Molecular neurodegeneration. 2020.", "tier": "A", "kind": "primary", "pmid": "32138754", "doi": "10.1186/s13024-020-00363-x", "url": "https://pubmed.ncbi.nlm.nih.gov/32138754/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "Parkin-PARIS-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC2", "CSC5" ] }, { "n": 14, "citation": "Jo A, Lee Y, Kam TI et al. PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease. Science translational medicine. 2021.", "tier": "A", "kind": "primary", "pmid": "34321320", "doi": "10.1126/scitranslmed.aax8891", "url": "https://pubmed.ncbi.nlm.nih.gov/34321320/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "Parkin-PARIS-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC2", "CSC5" ] }, { "n": 15, "citation": "Nguyen MK, McAvoy K, Liao SC et al. Mouse midbrain dopaminergic neurons survive loss of the PD-associated mitochondrial protein CHCHD2. Human molecular genetics. 2022.", "tier": "A", "kind": "primary", "pmid": "34791217", "doi": "10.1093/hmg/ddab329", "url": "https://pubmed.ncbi.nlm.nih.gov/34791217/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID34791217", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC2", "CSC5" ] }, { "n": 16, "citation": "Fan L, Zhang S, Li X et al. CHCHD2 p.Thr61Ile knock-in mice exhibit motor defects and neuropathological features of Parkinson's disease. Brain pathology (Zurich, Switzerland). 2023.", "tier": "A", "kind": "primary", "pmid": "36322611", "doi": "10.1111/bpa.13124", "url": "https://pubmed.ncbi.nlm.nih.gov/36322611/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID36322611", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC2", "CSC5" ] }, { "n": 17, "citation": "Di Maio R, Barrett PJ, Hoffman EK et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Science translational medicine. 2016.", "tier": "A", "kind": "primary", "pmid": "27280685", "doi": "10.1126/scitranslmed.aaf3634", "url": "https://pubmed.ncbi.nlm.nih.gov/27280685/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID27280685", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC1", "CSC5" ] }, { "n": 18, "citation": "Geibl FF, Henrich MT, Xie Z et al. α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease. Molecular neurodegeneration. 2024.", "tier": "A", "kind": "primary", "pmid": "39379975", "doi": "10.1186/s13024-024-00756-2", "url": "https://pubmed.ncbi.nlm.nih.gov/39379975/", "status_flags": [ "UpdateOf: PMID38168401" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID39379975", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC2", "CSC5" ] }, { "n": 19, "citation": "Flønes IH, Toker L, Sandnes DA et al. Mitochondrial complex I deficiency stratifies idiopathic Parkinson's disease. Nature communications. 2024.", "tier": "A", "kind": "primary", "pmid": "38684731", "doi": "10.1038/s41467-024-47867-4", "url": "https://pubmed.ncbi.nlm.nih.gov/38684731/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID38684731", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC1", "CSC4", "CSC5" ] }, { "n": 20, "citation": "Kokotos AC, Antoniazzi AM, Unda SR et al. Phosphoglycerate kinase is a central leverage point in Parkinson's disease-driven neuronal metabolic deficits. Science advances. 2024.", "tier": "A", "kind": "primary", "pmid": "39167658", "doi": "10.1126/sciadv.adn6016", "url": "https://pubmed.ncbi.nlm.nih.gov/39167658/", "status_flags": [ "UpdateOf: PMID37873141" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID39167658", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC2", "CSC5" ] }, { "n": 21, "citation": "Fang TZ, Sun Y, Pearce AC et al. Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model. Nature communications. 2023.", "tier": "A", "kind": "primary", "pmid": "37957154", "doi": "10.1038/s41467-023-42876-1", "url": "https://pubmed.ncbi.nlm.nih.gov/37957154/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID37957154", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC2", "CSC5" ] }, { "n": 22, "citation": "Du S, Long Q, Zhou Y et al. Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson's disease models. Cell. 2026.", "tier": "A", "kind": "primary", "pmid": "41856111", "doi": "10.1016/j.cell.2026.02.023", "url": "https://pubmed.ncbi.nlm.nih.gov/41856111/", "status_flags": [ "ErratumIn: PMID42140184" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID41856111", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC2", "CSC5" ] }, { "n": 23, "citation": "Matheoud D, Cannon T, Voisin A et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-/- mice. Nature. 2019.", "tier": "A", "kind": "primary", "pmid": "31316206", "doi": "10.1038/s41586-019-1405-y", "url": "https://pubmed.ncbi.nlm.nih.gov/31316206/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID31316206", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC2", "CSC5" ] }, { "n": 24, "citation": "Tanner CM, Kamel F, Ross GW et al. Rotenone, paraquat, and Parkinson's disease. Environmental health perspectives. 2011.", "tier": "A", "kind": "primary", "pmid": "21269927", "doi": "10.1289/ehp.1002839", "url": "https://pubmed.ncbi.nlm.nih.gov/21269927/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID21269927", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC1", "CSC5" ] }, { "n": 25, "citation": "Jishi A, Hu D, Shang Y et al. BCKDK loss impairs mitochondrial Complex I activity and drives alpha-synuclein aggregation in models of Parkinson's disease. Acta neuropathologica communications. 2024.", "tier": "A", "kind": "primary", "pmid": "39709505", "doi": "10.1186/s40478-024-01915-8", "url": "https://pubmed.ncbi.nlm.nih.gov/39709505/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID39709505", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC2", "CSC5" ] }, { "n": 26, "citation": "Siuda J, Jasinska-Myga B, Boczarska-Jedynak M et al. Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study. Parkinsonism & related disorders. 2014.", "tier": "A", "kind": "primary", "pmid": "25226871", "doi": "10.1016/j.parkreldis.2014.08.019", "url": "https://pubmed.ncbi.nlm.nih.gov/25226871/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID25226871", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC2", "CSC5" ] }, { "n": 27, "citation": "Wei W, Keogh MJ, Wilson I et al. Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta neuropathologica communications. 2017.", "tier": "A", "kind": "primary", "pmid": "28153046", "doi": "10.1186/s40478-016-0404-6", "url": "https://pubmed.ncbi.nlm.nih.gov/28153046/", "status_flags": [ "ErratumIn: PMID28228164" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID28153046", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC1", "CSC4", "CSC5" ] }, { "n": 28, "citation": "Cui L, Jeong H, Borovecki F et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006.", "tier": "A", "kind": "primary", "pmid": "17018277", "doi": "10.1016/j.cell.2006.09.015", "url": "https://pubmed.ncbi.nlm.nih.gov/17018277/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID17018277", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC3", "CSC5" ] }, { "n": 29, "citation": "Weydt P, Pineda VV, Torrence AE et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell metabolism. 2006.", "tier": "A", "kind": "primary", "pmid": "17055784", "doi": "10.1016/j.cmet.2006.10.004", "url": "https://pubmed.ncbi.nlm.nih.gov/17055784/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID17055784", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC3", "CSC5" ] }, { "n": 30, "citation": "Chandra A, Sharma A, Calingasan NY et al. Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease. Human molecular genetics. 2016.", "tier": "A", "kind": "primary", "pmid": "27008868", "doi": "10.1093/hmg/ddw095", "url": "https://pubmed.ncbi.nlm.nih.gov/27008868/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID27008868", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC3", "CSC5" ] }, { "n": 31, "citation": " et al. Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites. Human molecular genetics. 2020.", "tier": "A", "kind": "primary", "pmid": "30768179", "doi": "10.1093/hmg/ddy430", "url": "https://pubmed.ncbi.nlm.nih.gov/30768179/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "HD-iPSC-Consortium", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph9, 1:Results:paragraph11, 1:Results:paragraph14. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC3", "CSC5", "CH" ] }, { "n": 32, "citation": "Chen X, Bonilla E, Sciacco M et al. Paucity of deleted mitochondrial DNAs in brain regions of Huntington's disease patients. Biochimica et biophysica acta. 1995.", "tier": "A", "kind": "primary", "pmid": "7599213", "doi": "10.1016/0925-4439(95)00032-y", "url": "https://pubmed.ncbi.nlm.nih.gov/7599213/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID7599213", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC1", "CSC5" ] }, { "n": 33, "citation": "Swerdlow RH, Parks JK, Cassarino DS et al. Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Biochemical and biophysical research communications. 1999.", "tier": "A", "kind": "primary", "pmid": "10441489", "doi": "10.1006/bbrc.1999.1095", "url": "https://pubmed.ncbi.nlm.nih.gov/10441489/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID10441489", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC1", "CSC5" ] }, { "n": 34, "citation": "Hamilton J, Pellman JJ, Brustovetsky T et al. Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease. Human molecular genetics. 2016.", "tier": "A", "kind": "primary", "pmid": "27131346", "doi": "10.1093/hmg/ddw133", "url": "https://pubmed.ncbi.nlm.nih.gov/27131346/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID27131346", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC3", "CSC5" ] }, { "n": 35, "citation": "Oláh J, Klivényi P, Gardián G et al. Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. The FEBS journal. 2008.", "tier": "A", "kind": "primary", "pmid": "18721135", "doi": "10.1111/j.1742-4658.2008.06612.x", "url": "https://pubmed.ncbi.nlm.nih.gov/18721135/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID18721135", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC1", "CSC5" ] }, { "n": 36, "citation": "Hamilton J, Brustovetsky T, Khanna R et al. Mutant huntingtin does not cross the mitochondrial outer membrane. Human molecular genetics. 2020.", "tier": "A", "kind": "primary", "pmid": "32821928", "doi": "10.1093/hmg/ddaa185", "url": "https://pubmed.ncbi.nlm.nih.gov/32821928/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID32821928", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC3", "CSC5" ] }, { "n": 37, "citation": "Soyal SM, Felder TK, Auer S et al. A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Human molecular genetics. 2012.", "tier": "A", "kind": "primary", "pmid": "22589246", "doi": "10.1093/hmg/dds177", "url": "https://pubmed.ncbi.nlm.nih.gov/22589246/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID22589246", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC3", "CSC5" ] }, { "n": 38, "citation": "Du H, Guo L, Fang F et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nature medicine. 2008.", "tier": "A", "kind": "primary", "pmid": "18806802", "doi": "10.1038/nm.1868", "url": "https://pubmed.ncbi.nlm.nih.gov/18806802/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID18806802", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC2", "CSC5" ] }, { "n": 39, "citation": "Samanta S, Akhter F, Roy A et al. New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease. Brain : a journal of neurology. 2024.", "tier": "A", "kind": "primary", "pmid": "38146639", "doi": "10.1093/brain/awad432", "url": "https://pubmed.ncbi.nlm.nih.gov/38146639/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID38146639", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC2", "CSC5" ] }, { "n": 40, "citation": "Jadiya P, Kolmetzky DW, Tomar D et al. Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. Nature communications. 2019.", "tier": "A", "kind": "primary", "pmid": "31467276", "doi": "10.1038/s41467-019-11813-6", "url": "https://pubmed.ncbi.nlm.nih.gov/31467276/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "NCLX-calcium-platform", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph3, 1:Results:paragraph7, 1:Results:paragraph9, 1:Results:paragraph14. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC2", "CSC5" ] }, { "n": 41, "citation": "Jadiya P, Cohen HM, Kolmetzky DW et al. Neuronal loss of NCLX-dependent mitochondrial calcium efflux mediates age-associated cognitive decline. iScience. 2023.", "tier": "A", "kind": "primary", "pmid": "36936788", "doi": "10.1016/j.isci.2023.106296", "url": "https://pubmed.ncbi.nlm.nih.gov/36936788/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "NCLX-calcium-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC2", "CSC5" ] }, { "n": 42, "citation": "Jadiya P, Berezhnaya E, Kolmetzky DW et al. Genetic ablation of neuronal mitochondrial calcium uptake impedes Alzheimer's disease progression. The EMBO journal. 2026.", "tier": "A", "kind": "primary", "pmid": "42174122", "doi": "10.1038/s44318-026-00809-w", "url": "https://pubmed.ncbi.nlm.nih.gov/42174122/", "status_flags": [ "UpdateOf: PMID37904949" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "NCLX-calcium-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC2", "CSC5" ] }, { "n": 43, "citation": "Swerdlow RH, Parks JK, Cassarino DS et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology. 1997.", "tier": "A", "kind": "primary", "pmid": "9339668", "doi": "10.1212/wnl.49.4.918", "url": "https://pubmed.ncbi.nlm.nih.gov/9339668/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "AD-cybrid-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC2", "CSC5" ] }, { "n": 44, "citation": "Khan SM, Cassarino DS, Abramova NN et al. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Annals of neurology. 2000.", "tier": "A", "kind": "primary", "pmid": "10939564", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/10939564/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "AD-cybrid-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC2", "CSC5" ] }, { "n": 45, "citation": "Silva DF, Santana I, Esteves AR et al. Prodromal metabolic phenotype in MCI cybrids: implications for Alzheimer's disease. Current Alzheimer research. 2013.", "tier": "A", "kind": "primary", "pmid": "22746213", "doi": "10.2174/1567205011310020008", "url": "https://pubmed.ncbi.nlm.nih.gov/22746213/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "AD-cybrid-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC1", "CSC5" ] }, { "n": 46, "citation": "Ito S, Ohta S, Nishimaki K et al. Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 1999.", "tier": "A", "kind": "primary", "pmid": "10051601", "doi": "10.1073/pnas.96.5.2099", "url": "https://pubmed.ncbi.nlm.nih.gov/10051601/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID10051601", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC2", "CSC5" ] }, { "n": 47, "citation": "Weidling IW, Wilkins HM, Koppel SJ et al. Mitochondrial DNA Manipulations Affect Tau Oligomerization. Journal of Alzheimer's disease : JAD. 2020.", "tier": "A", "kind": "primary", "pmid": "32804126", "doi": "10.3233/JAD-200286", "url": "https://pubmed.ncbi.nlm.nih.gov/32804126/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "AD-cybrid-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC2", "CSC5" ] }, { "n": 48, "citation": "Kemna RE, Kueck PJ, Honea R et al. Mitochondrial DNA affects tau phosphorylation in aging and Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.", "tier": "A", "kind": "primary", "pmid": "40596736", "doi": "10.1002/alz.70390", "url": "https://pubmed.ncbi.nlm.nih.gov/40596736/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "AD-cybrid-platform", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC1", "CSC5" ] }, { "n": 49, "citation": "Han J, Park H, Maharana C et al. Alzheimer's disease-causing presenilin-1 mutations have deleterious effects on mitochondrial function. Theranostics. 2021.", "tier": "A", "kind": "primary", "pmid": "34522215", "doi": "10.7150/thno.59776", "url": "https://pubmed.ncbi.nlm.nih.gov/34522215/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID34522215", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC2", "CSC5" ] }, { "n": 50, "citation": "Lee H, Cho S, Kim MJ et al. ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes. Cell reports. 2023.", "tier": "A", "kind": "primary", "pmid": "37777962", "doi": "10.1016/j.celrep.2023.113183", "url": "https://pubmed.ncbi.nlm.nih.gov/37777962/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID37777962", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC2", "CSC5" ] }, { "n": 51, "citation": "Wilson EN, Wang C, Swarovski MS et al. TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models. Nature neuroscience. 2024.", "tier": "A", "kind": "primary", "pmid": "38539014", "doi": "10.1038/s41593-024-01610-w", "url": "https://pubmed.ncbi.nlm.nih.gov/38539014/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID38539014", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC2", "CSC5" ] }, { "n": 52, "citation": "Parone PA, Da Cruz S, Han JS et al. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013.", "tier": "A", "kind": "primary", "pmid": "23486940", "doi": "10.1523/JNEUROSCI.1119-12.2013", "url": "https://pubmed.ncbi.nlm.nih.gov/23486940/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID23486940", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C52", "CSC2", "CSC5", "CH" ] }, { "n": 53, "citation": "Martin LJ, Gertz B, Pan Y et al. The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Experimental neurology. 2009.", "tier": "A", "kind": "primary", "pmid": "19272377", "doi": "10.1016/j.expneurol.2009.02.015", "url": "https://pubmed.ncbi.nlm.nih.gov/19272377/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID19272377", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C53", "CSC2", "CSC5" ] }, { "n": 54, "citation": "Yu CH, Davidson S, Harapas CR et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020.", "tier": "A", "kind": "primary", "pmid": "33031745", "doi": "10.1016/j.cell.2020.09.020", "url": "https://pubmed.ncbi.nlm.nih.gov/33031745/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID33031745", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C54", "CSC2", "CSC5" ] }, { "n": 55, "citation": "Cheng M, Lu D, Li K et al. Mitochondrial respiratory complex IV deficiency recapitulates amyotrophic lateral sclerosis. Nature neuroscience. 2025.", "tier": "A", "kind": "primary", "pmid": "40069360", "doi": "10.1038/s41593-025-01896-4", "url": "https://pubmed.ncbi.nlm.nih.gov/40069360/", "status_flags": [ "ErratumIn: PMID40119207" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID40069360", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C55", "CSC2", "CSC5" ] }, { "n": 56, "citation": "Israelson A, Arbel N, Da Cruz S et al. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron. 2010.", "tier": "A", "kind": "primary", "pmid": "20797535", "doi": "10.1016/j.neuron.2010.07.019", "url": "https://pubmed.ncbi.nlm.nih.gov/20797535/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID20797535", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C56", "CSC2", "CSC5" ] }, { "n": 57, "citation": "Zhang F, Wang W, Siedlak SL et al. Miro1 deficiency in amyotrophic lateral sclerosis. Frontiers in aging neuroscience. 2015.", "tier": "A", "kind": "primary", "pmid": "26074815", "doi": "10.3389/fnagi.2015.00100", "url": "https://pubmed.ncbi.nlm.nih.gov/26074815/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID26074815", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C57", "CSC1", "CSC5" ] }, { "n": 58, "citation": " , et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 2017.", "tier": "A", "kind": "rct", "pmid": "28522181", "doi": "10.1016/S1474-4422(17)30115-1", "url": "https://pubmed.ncbi.nlm.nih.gov/28522181/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID28522181", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C58", "CSC6" ] }, { "n": 59, "citation": "Witzel S, Maier A, Steinbach R et al. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA neurology. 2022.", "tier": "A", "kind": "primary", "pmid": "35006266", "doi": "10.1001/jamaneurol.2021.4893", "url": "https://pubmed.ncbi.nlm.nih.gov/35006266/", "status_flags": [ "ErratumIn: PMID35696158" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "German-edaravone-cohort", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C59", "CSC6" ] }, { "n": 60, "citation": "Cudkowicz ME, van den Berg LH, Shefner JM et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. The Lancet. Neurology. 2013.", "tier": "A", "kind": "rct", "pmid": "24067398", "doi": "10.1016/S1474-4422(13)70221-7", "url": "https://pubmed.ncbi.nlm.nih.gov/24067398/", "status_flags": [ "ErratumIn: PMID not supplied" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID24067398", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C60", "CSC6" ] }, { "n": 61, "citation": "Lenglet T, Lacomblez L, Abitbol JL et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. European journal of neurology. 2014.", "tier": "A", "kind": "rct", "pmid": "24447620", "doi": "10.1111/ene.12344", "url": "https://pubmed.ncbi.nlm.nih.gov/24447620/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID24447620", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C61", "CSC6" ] }, { "n": 62, "citation": "Kaufmann P, Thompson JL, Levy G et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Annals of neurology. 2009.", "tier": "A", "kind": "rct", "pmid": "19743457", "doi": "10.1002/ana.21743", "url": "https://pubmed.ncbi.nlm.nih.gov/19743457/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID19743457", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C62", "CSC6" ] }, { "n": 63, "citation": "Vieira FG, LaDow E, Moreno A et al. Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PloS one. 2014.", "tier": "A", "kind": "primary", "pmid": "25526593", "doi": "10.1371/journal.pone.0091608", "url": "https://pubmed.ncbi.nlm.nih.gov/25526593/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID25526593", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C63", "CSC2", "CSC6" ] }, { "n": 64, "citation": " , Beal MF, Oakes D et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA neurology. 2014.", "tier": "A", "kind": "rct", "pmid": "24664227", "doi": "10.1001/jamaneurol.2014.131", "url": "https://pubmed.ncbi.nlm.nih.gov/24664227/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID24664227", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C64", "CSC6" ] }, { "n": 65, "citation": " , Kieburtz K, Tilley BC et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015.", "tier": "A", "kind": "rct", "pmid": "25668262", "doi": "10.1001/jama.2015.120", "url": "https://pubmed.ncbi.nlm.nih.gov/25668262/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID25668262", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C65", "CSC6" ] }, { "n": 66, "citation": " et al. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Annals of internal medicine. 2020.", "tier": "A", "kind": "rct", "pmid": "32227247", "doi": "10.7326/M19-2534", "url": "https://pubmed.ncbi.nlm.nih.gov/32227247/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID32227247", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C66", "CSC6" ] }, { "n": 67, "citation": "Payne T, Appleby M, Buckley E et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2023.", "tier": "A", "kind": "rct", "pmid": "37246815", "doi": "10.1002/mds.29450", "url": "https://pubmed.ncbi.nlm.nih.gov/37246815/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID37246815", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph8, 2:Results:paragraph0, 2:Results:paragraph5, 2:Results:paragraph6, 2:Results:paragraph7, 2:Results:paragraph8. No complete-paper or supplement audit claimed.", "carries_claims": [ "C67", "CSC6", "CH" ] }, { "n": 68, "citation": "Brakedal B, Dölle C, Riemer F et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell metabolism. 2022.", "tier": "A", "kind": "rct", "pmid": "35235774", "doi": "10.1016/j.cmet.2022.02.001", "url": "https://pubmed.ncbi.nlm.nih.gov/35235774/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID35235774", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C68", "CSC6" ] }, { "n": 69, "citation": "Berven H, Kverneng S, Sheard E et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nature communications. 2023.", "tier": "A", "kind": "rct", "pmid": "38016950", "doi": "10.1038/s41467-023-43514-6", "url": "https://pubmed.ncbi.nlm.nih.gov/38016950/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID38016950", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C69", "CSC6" ] }, { "n": 70, "citation": "McGarry A, McDermott M, Kieburtz K et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017.", "tier": "A", "kind": "rct", "pmid": "27913695", "doi": "10.1212/WNL.0000000000003478", "url": "https://pubmed.ncbi.nlm.nih.gov/27913695/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-07", "status_checked_on": "2026-10-07", "study_id": "PMID27913695", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed.", "carries_claims": [ "C70", "CSC6" ] } ], "independence_basis": { "required": true, "lines": [ { "label": "Mitochondrial transcription loss", "sources": [ 1 ], "excludes_error": "TFAM disruption excludes protein-overexpression as a required route in this model." }, { "label": "Adult quality-control loss and mediator subtraction", "sources": [ 10, 5 ], "excludes_error": "Adult PARIS necessity and combined mtDNA stress test developmental compensation and single-lesion sufficiency differently." }, { "label": "Mitochondrial-genome respiratory editing", "sources": [ 55 ], "excludes_error": "Rat complex-IV editing tests a different respiratory lesion and neuronal vulnerability; exact correction details remain unexamined." } ], "shared_failure_mode_checked": true, "note": "SC2 convergence uses different endogenous perturbations and mice/rats rather than simply counting TH-stained cells or multiple papers. PARIS extensions, NCLX descendants and cybrid variants share platforms; uncertain cohort overlap is not claimed resolved. Lesion-to-injury causal convergence does not identify the common spontaneous initiator. Ndufs2 dysfunction and CypD fatal-paralysis nulls are explicit discriminators, not positive death or trajectory lines." }, "consensus_validation": { "completed": true, "status": "documented_historical_discovery_and_reconciliation", "provider": "Consensus", "provider_mode": "Historical browser/connector use as recorded in the source artifacts", "local_audit_date": "2026-10-09", "primary_comparison_count": null, "reported_usage": [], "grade_changed": false, "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "Multiple independent causal lines across mouse, rat, fly and human cellular systems, but substantial heterogeneity in preparation and controls and unreconciled discrepancies (complex-I subtype variation, cybrid nuclear background, CypD survival effects) limit reproducibility. Access depth is not a determinant. Confidence reflects evidence density and reproducibility, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "Scope-matched SC5 gives Γ. Endogenous mitochondrial lesions demonstrate convergent model causality (SC2 Ζ), and HD biogenesis has contextual contribution (SC3 Ε). Neither set identifies age-related respiratory failure as the spontaneous upstream cause across disease classes. The registered phrase sporadic Huntington disease is scientifically ill-posed: the examined HTT disease is genetically initiated, and is retained as an explicit counterexample rather than silently recast." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "Multiple independent causal lines across mouse, rat, fly and human cellular systems, but substantial heterogeneity in preparation and controls and unreconciled discrepancies (complex-I subtype variation, cybrid nuclear background, CypD survival effects) limit reproducibility. Access depth is not a determinant. Confidence reflects evidence density and reproducibility, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "Scope-matched SC5 gives Γ. Endogenous mitochondrial lesions demonstrate convergent model causality (SC2 Ζ), and HD biogenesis has contextual contribution (SC3 Ε). Neither set identifies age-related respiratory failure as the spontaneous upstream cause across disease classes. The registered phrase sporadic Huntington disease is scientifically ill-posed: the examined HTT disease is genetically initiated, and is retained as an explicit counterexample rather than silently recast." }, "independent_blinded_audit": false, "raw_receipts": [ { "path": "deliverables\\hsef_v53_popularity_ranks_26_30_2026-10-07\\mitochondrial-cascade\\consensus\\broad-browser-snapshot.txt", "sha256": "7319f5d80b4879d542e6174819e64a155e1f725e783d0a0a3561fb111f89c1d0" }, { "path": "deliverables\\hsef_v53_popularity_ranks_26_30_2026-10-07\\mitochondrial-cascade\\consensus\\query-ledger.json", "sha256": "880c12d00c0ff6433275c75b851647ea5a70bd5ca2106d459d7c1b5f8cdd01b5" }, { "path": "deliverables\\hsef_v53_popularity_ranks_26_30_2026-10-07\\mitochondrial-cascade\\consensus\\reconciliation.md", "sha256": "38686f286213850c08f553e2c2eedbcfeb0efcbebf5e9565db8bde5f6585b50e" }, { "path": "deliverables\\hsef_v53_popularity_ranks_26_30_2026-10-07\\mitochondrial-cascade\\consensus\\targeted-browser-snapshot.txt", "sha256": "5842683b7005cd3a353735194269ccf9e2da06daf359606e267992d23c2abf91" } ], "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record." } }